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II. List of abbreviations 
 
II.A Used abbreviations 
 
°C  Degree Celsius 
µ  Micro 
2logFC Log2 FoldChange 
3’  Three prime end of nucleic acid 
5’  Five prime end of nucleic acid 
A  Ampere 
ADP  Adenosine diphosphate 
AG  Research group 
AP  Anterior – posterior 
Astro  Astrocytes 
ATP  Adenosine triphosphate 
B6  C57Bl/6N inbred mouse strain 
bp  Base pair 
BP  Biological process 
BSE  Bovine spongiform encephalopathy, “mad cow” disease 
CC  Cellular compartment 
cDNA  Complementary DNA 
CHO  Carbohydrate (N-linked glycosylation site) 
CJD  Creutzfeldt-Jakob disease 
Cnx43  Connexin 43, gap junction alpha-1 protein (GJA1)  
CoQ  Coenzyme Q10, ubiquinone 
Cre  Cre recombinase 
CT  Cycle threshold 
d  Day 
Da  Dalton 
DEG  Differentially expressed gene 
DNA  Deoxyribonucleic acid 
dNTP  Deoxynucleoside triphosphate 
DZNE  German Center for Neurodegenerative Diseases 
e-  Electron 
EEG  Electroencephalography 
EMG  Electromyography 
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FAD  Flavin adenine dinucleotide (FAD / FADH2) 
FBS  Fetal bovine serum 
FFI  Fatal familial insomnia 
For  Forward 
FRT  Flippase recognition target 
g  Earth's gravitational acceleration 
G  Gauge 
g  Gram 
GABA  GABAergic neurons 
Gad2  Glutamate decarboxylase 2 
Glut  Glutamatergic neurons 
GO  Gene ontology 
GPI  Glycophosphatidylinositol 
GSS  Gerstmann-Sträussler-Scheinker syndrome 
h  Hour 
H+  Proton 
HA  Hemagglutinin 
HRP  Horseradish peroxidase 
Hz  Hertz 
IEGs  Immediate early genes 
IP  Immunoprecipitation 
IPA  Ingenuity Pathway Analysis 
IRES  Internal ribosomal entry site 
k  Kilo 
l  Liter 
lfcSE  Log2 FoldChange Standard Error 
loxP  Cre recombinase target sequence 
m  Meter 
m  Milli 
M  Molar 
MF  Molecular function 
min  Minute 
MIT  Massachusetts Institute of Technology 
ML  Medial – lateral 
mRNA  Messenger ribonucleic acid 
n  Nano 
n  number, sample size 
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NAD  Nicotinamide adenine dinucleotide (NAD+ / NADH+H+) 
NBH  Normal brain homogenate 
NCBI  National Center for Biotechnology Information 
ND  Neurodegenerative disease 
NREM  Non rapid eye movement sleep, deep slow wave sleep 
ORF  Open reading frame 
padj  Adjusted p-value, false discovery rate (FDR) 
PAGE  Polyacrylamide gel electrophoresis 
PBS  Phosphate-buffered saline 
PCR  Polymerase chain reaction 
pH  Negative of logarithm to base 10 of hydrogen ion activity 
PK  Proteinase K 
PMCA  Protein misfolding cyclic amplification 
POL  Polymerase 
Prnp  Prion protein gene 
PrP 27-30 N-terminally truncated PrPSc by proteinase K 
PrP  Prion protein 
PrPC  Endogenous, cellular isoform of prion protein 
PrPSc  Misfolded, pathogenic isoform of prion protein 
PV  Parvalbumin neurons 
pval  P-value, probability value 
Pvalb  Parvalbumin 
qPCR  Real-time quantitative PCR 
REM  Rapid eye movement sleep, paradoxical sleep 
Rev  Reverse 
REV-ERBs Orphan nuclear hormone receptors 
RML  Mouse adapted Rocky Mountain Laboratory scrapie strain 
RNA  Ribonucleic acid 
RNase  Ribonuclease 
RORs  Retinoid related orphan receptors 
ROS  Reactive oxygen species 
RPKM  Reads per kilobase per million mapped reads 
Rpl22  Large subunit ribosomal protein 22 
rpm  Revolutions per minute 
RT  Reverse transcription, reverse transcriptase 
RT  Room temperature 
Rtag  RiboTag 
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s  Second 
S2  Biosafety containment level 2 
S4  129S4/SvJae inbred mouse strain 
SCN  Suprachiasmatic nucleus 
S-S  Disulfide bond 
SST  Somatostatin, somatostatin neurons 
TSEs  Transmissible spongiform encephalopathies 
U  Unit 
UER  Unique exon read 
UPR  Unfolded protein response 
UTR  Untranslated region 
V  Volt 
Vglut2  Vesicular glutamate transporter 2 
vs.  Versus 
wpi  Weeks post infection 
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II.B Primary nucleobases 
 
Name    1 letter code 
Adenine   A 
Cytosine   C 
Guanine   G 
Thymine   T 
Uracil    U 
 
II.C Proteinogenic amino acids  
 
Name    1 letter code  3 letter code 
Alanine   A   Ala 
Arginine   R   Arg 
Asparagine   N   Asn 
Aspartic acid   D   Asp 
Cysteine   C   Cys 
Glutamic acid   E   Glu 
Glutamine   Q   Gln 
Glycine   G   Gly 
Histidine   H   His 
Isoleucine   I   Ile 
Leucine   L   Leu 
Lysine    K   Lys 
Methionine   M   Met 
Phenylalanine   F   Phe 
Proline    P   Pro 
Pyrrolysine   O   Pyl 
Selenocysteine  U   Sec 
Serine    S   Ser 
Threonine   T   Thr 
Tryptophan   W   Trp 
Tyrosine   Y   Tyr 
Valine    V   Val 
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1. Introduction 
1.1 Neurodegenerative diseases 
 
Neurodegenerative diseases (ND) are a heterogeneous group of disorders of the 
nervous system caused by redundant aggregation of misfolded, toxic proteins and 
dysfunctional trafficking of proteins. Examples of NDs are Alzheimer’s disease, 
Parkinson’s disease, Huntington’s disease, amyotrophic lateral sclerosis and 
transmissible spongiform encephalopathies (TSEs) (Taylor et al. 2002, Dobson 
2003, Rubinsztein 2006, Ramanan and Saykin 2013, Sheikh et al. 2013). 
NDs are associated with the accumulation and aggregation of abnormal or 
misfolded proteins. Neuronal cell death is common, leading to degeneration of the 
structure and function of the nervous system. Depending on the affected brain 
region the neurodegeneration causes movement problems or impairment of mental 
functioning. There are several NDs and they all differ in etiology and their 
morphological and pathophysiological features (Nieoullon 2011, Ramanan and 
Saykin 2013, Sheikh et al. 2013). 
In addition to protein misfolding and aggregation, factors leading to and associated 
with NDs are mitochondrial dysfunction, altered protein modifications, oxidative 
stress, free radical formation, metal dyshomeostasis and aging (Figure 1.1) (Dobson 
2003, Sheikh et al. 2013). Nervous system cell pathways altered in NDs can be 
functionally grouped into intracellular mechanisms (apoptosis, autophagy, 
mitochondrial functions, oxidative stress response, proteasome), local tissue 
environment (cell adhesion, endocytosis, neurotransmission), systemic environment 
(inflammation, immune system) and development and aging (epigenetics, 
telomeres) (Ramanan and Saykin 2013). 
In addition to genetic risk factors like familial mutations leading to NDs, the risk to 
suffer from any ND increases with age. Other risk factors depend on geography, 
hereditary, viral and toxicological exposure (Emard et al. 1995). Due to the 
demographic change in society, especially in the industrialized countries, NDs are 
becoming an ever-increasing problem (Brookmeyer et al. 2007). 
The exact mechanism of how misfolded, aggregated proteins lead to toxicity and 
neurodegeneration is still unknown. For therapeutic approaches the mechanism of 
aggregation and toxicity of the disease related proteins have to be further 
investigated. Therapeutic approaches are needed because NDs currently take up a 
very large proportion of the massive amount of money spent on health care and the 
Introduction 
 
10 
 
ever-expanding aged population will amplify this problem in the future (Taylor et al. 
2002, Andlin-Sobocki et al. 2005, Brookmeyer et al. 2007, Katsuno et al. 2012, 
Panegyres and Armari 2013).  
 
 
Figure 1.1: Factors causing and associated with neurodegenerative diseases leading to 
neuronal death. (Sheikh et al. 2013) 
 
1.2 Selective vulnerability 
 
NDs initially affect only specific regions of the brain, a phenomenon known as 
selective vulnerability (Figure 1.2). For example, brain regions important for motor 
control are severely damaged in Huntington’s disease and Parkinson’s disease, 
while brain regions important for memory are severely damaged in Alzheimer’s 
disease (Table 1.2). The fact why other brain regions remain unaffected in these 
diseases is still unknown (Guentchev et al. 1999, Jackson 2014, Mattsson et al. 
2016). 
Since these and many other neurodegenerative diseases are thought to be caused 
by misfolding and aggregation of specific proteins, a reasonable explanation is that 
the most affected regions have the highest expression levels of the toxic proteins. 
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However, this is not the case and something else must be determining selective 
vulnerability (Jackson 2014).  
 
 
Figure 1.2: Selective vulnerability of neuropathological changes, namely neuronal loss 
(triangles) and spongiosis (circles), in fatal familial insomnia (FFI) and Creutzfeldt-Jakob 
disease (CJD). Both diseases are linked to a codon 178 mutation (D178N), but segregated 
by a codon 129 polymorphism. (Montagna et al. 2003) 
 
Table 1.2: Examples of NDs, their major disease related genes or proteins and their most 
affected brain regions 
Disease Related gene / protein Targeted region 
Alzheimer’s disease Amyloid precursor protein, presinilin 1+2, tau protein Hippocampus, cortex 
Amyotrophic lateral sclerosis Superoxide dismutase 1 Motor cortex 
Creutzfeldt-Jakob disease (CJD) Prion protein Cortex 
Fatal familial insomnia (FFI) Prion protein Thalamus 
Frontotemporal dementia Tau protein, granulin Frontal lobe, temporal lobe 
Gerstmann-Sträussler-
Scheinker syndrome (GSS) Prion protein Cerebellum 
Huntington’s disease Huntingtin Striatum, cortex 
Parkinson’s disease Alpha-synuclein Substantia nigra 
 
Specific brain regions possess specific brain cells and the phenomenon of selective 
vulnerability could be caused by these specific brain cells in these regions having 
unique strategies and capacities to cope with various disease related protein 
conformers. Furthermore, next to the complete proteasome the protein quality 
control machinery differs between different cell types due to different compilations of 
machinery components and clients and these differences strongly influence 
selective vulnerability (Jackson 2014). It is also discussed for some diseases, 
including TSEs, if a cofactor needed for misfolding of the disease related protein is 
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available only in these specific cell types (Prusiner 1998, Colby and Prusiner 2011). 
A better understanding of the phenomenon of selective vulnerability could support 
therapeutic approaches for many neurodegenerative diseases (Jackson 2014). 
 
1.3 Transmissible spongiform encephalopathies 
 
TSEs, also known as prion diseases, are a group of rare, transmissible, infectious 
and always fatal neurodegenerative disorders affecting the nervous system of 
humans and other mammals. TSEs are caused by prions, the misfolded, 
aggregated and infectious form of the endogenous prion protein (Prusiner 1982, 
Fields et al. 2001, Colby and Prusiner 2011, Whitechurch et al. 2017). Examples of 
TSEs are Creutzfeldt-Jakob disease, fatal familial insomnia,  
Gerstmann-Sträussler-Scheinker syndrome and kuru in humans, bovine spongiform 
encephalopathy (BSE, “mad cow” disease) in cattle and scrapie in sheep and goats 
(Table 1.3) (Colby and Prusiner 2011). 
 
Table 1.3: Prion diseases in humans and animals and the mechanism of pathogenesis 
(Colby and Prusiner 2011). 
Disease Host Mechanism of pathogenesis 
BSE Cattle Infection or sporadic 
Chronic wasting disease Deer, elk, 
moose 
Infection 
Exotic ungulate 
encephalopathy 
Greater kudu, 
nyala, oryx 
Infection with prion-contaminated meat and 
bone meal 
Familial CJD Humans Germline mutations in the PRNP gene 
Feline spongiform 
encephalopathy 
Felidae Infection with prion-contaminated bovine 
tissues or meat and bone meal 
FFI Humans Germline mutations in the PRNP gene 
GSS Humans Germline mutations in the PRNP gene 
Iatrogenic CJD Humans Infection from prion-contaminated human 
growth hormone, medical equipment 
Kuru Humans Infection through ritualistic cannibalism 
Scrapie Sheep, goats Infection 
Sporadic CJD Humans Somatic mutation or spontaneous conversion 
of PrPC to PrPSc 
Sporadic fatal insomnia Humans Somatic mutation or spontaneous conversion 
of PrPC to PrPSc 
Transmissible mink 
encephalopathy 
Mink Infection with prions from sheep or cattle 
Variant CJD Humans Infection from bovine prions 
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1.3.1 Prions 
 
Prions (proteinacious infectious particles) are infectious proteins causing TSEs, the 
only known infectious protein misfolding disorders (Prusiner 1982, Ma and Wang 
2014). They have been identified in both fungi and mammals. In mammals they are 
the misfolded, disease causing form of the prion protein (PrP), an endogenous 
glycoprotein which is located primarily on the surface of central nervous system 
cells (Prusiner 1998, Aguzzi and Calella 2009, Colby and Prusiner 2011, 
Whitechurch et al. 2017) . 
The protein-only hypothesis proposes that prions consist only of protein and  
self-replicate without any nucleic acids (Safar et al. 2005b, Ma and Wang 2014). 
There is still some controversy about the protein-only hypothesis. Some researchers 
suppose that prion diseases are caused by slow viruses (Manuelidis 2007, 
Manuelidis et al. 2007), a self-replicating nucleic acid bound to PrP (Virino) 
(Dickinson and Outram 1988) or bacteria (Tiwana et al. 1999, Bastian and Foster 
2001). Nonetheless, the protein-only hypothesis is widely accepted in the prion field 
(Aguzzi and Calella 2009, Soto 2011). 
While in mammals prions are definitely fatal pathogens, in lower eukaryotes they 
can be either harmful or beneficial to the host organism (True and Lindquist 2000, 
True et al. 2004, Tyedmers et al. 2008). Indeed, this concept has been exploited to 
study the replication and transmission of amyloid proteins of these organisms 
(Halfmann et al. 2012, Hofmann and Vorberg 2013, Krauss and Vorberg 2013). 
The natural function of PrP is still poorly understood. Prion diseases exist in genetic, 
sporadic and acquired forms. Prions replicate when normal cellular prion protein 
(PrPC) (Figure 1.3.1) misfolds into the disease-causing form (PrPSc) (Figure 1.3.1). 
PrPSc accumulates to high levels in the nervous system leading to nervous system 
dysfunction, neurodegeneration and eventually to death. Monomeric PrPSc forms 
dimers, then oligomers and finally large aggregates and amyloids (Figure 1.3.1). 
The amyloids can fragment to build seeds for transmission (Prusiner 1998, Fields et 
al. 2001, Aguzzi and Calella 2009, Colby and Prusiner 2011, Biasini et al. 2012, 
Prusiner 2013, Whitechurch et al. 2017).  
The singularity of prions compared to other pathogens like bacteria and viruses is 
that prions consist only of protein and are free from nucleic acids (Safar et al. 
2005b). Furthermore, prions are nonimmunogenic. The misfolded, pathogenic 
isoform of the prion protein fails to activate an immune response in mammals, like 
that caused by bacteria and viruses (Prusiner et al. 1993). Prion disease infection 
from one species to another is restricted by the so called species barrier. Crossing 
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to another species is more likely if the evolutionary relationship between host and 
new recipient is close so that their PrP sequences are very similar (Scott et al. 
1989). Astonishingly, this one protein, by misfolding, can lead to several different 
TSEs caused for example by mutations or polymorphism in the prion protein 
sequence or spontaneous misfolding. But even for the same prion disease like 
scrapie there are many different strains. Prion strains are phenotypic TSE variants 
causing disease with consistent characteristics, including specific incubation times 
and brain lesions. Importantly, different strains cannot be encoded by nucleic acid 
sequence or primary structure of the protein (Pattison and Millson 1961, Aguzzi et 
al. 2007). The strain difference has to be somehow encoded by higher structure 
conformations of PrPSc (Prusiner 1991, Telling et al. 1996, Whitechurch et al. 2017). 
 
 
Figure 1.3.1: Electron microscopy of negatively stained and ImmunoGold labeled prion 
proteins. A. PrPC, B. PrPSc, C. Prion aggregates consisting mainly of PrP 27–30; bar: 100nm 
(Prusiner 1998) 
 
1.3.2 Prion protein gene 
 
PrP is encoded by the nuclear gene PRNP (human: chromosome 20) / Prnp 
(mouse: chromosome 2) (Sparkes et al. 1986). Prnp is known in many species and 
its sequence is evolutionary highly conserved (Krakauer et al. 1996, van Rheede et 
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al. 2003). The complete open reading frame (ORF) of all mammalian PrP genes is 
located within one exon (Linden et al. 2008). Mouse, rat, bovine and sheep PrP 
genes consist of three exons, the last exon contains the ORF and the 3’untranslated 
region (UTR). Human PRNP and hamster Prnp have two exons and, again, the 
terminal exon contains the ORF. Gene expression is controlled by sequences in the 
5’flanking region, within the first intron and sequences in the 3’UTR (Figure 1.3.2) 
(Linden et al. 2008, Damberger et al. 2011). 
 
 
Figure 1.3.2: A. The murine Prnp gene consists of 3 exons. Exon 3 contains the complete 
ORF and a 3'UTR. B. Murine PrP consists of 254 amino acids including a 22 amino acid 
signal peptide, five octapeptide repeats, one disulfide bond (S-S) between cysteine residues 
178 and 213 and two potential sites for glycosylation (CHO) at residues 180 and 196. A GPI 
anchor is attached to the C-terminus of PrP at residue 231, replacing residues 232 to 254. 
C. Human PrP is 253 amino acids long with the same features as the mouse PrP. This 
diagram shows polymorphisms (boxes under the gene) and insertions, deletions and point 
mutations in the human PrP linked to familial prion disease. The asterisk (*) indicates a 
mutation caused stop codon and therefore a truncated protein. (Modified figure) (Manson 
and Tuzi 2001) 
 
PrP is expressed in many different tissues (skeletal muscle, kidney, heart, 
secondary lymphoid organs), but is most abundant in the adult central nervous 
system (Oesch et al. 1985, Ford et al. 2002, Peralta and Eyestone 2009). However, 
only a few cell types support aggregation of PrPSc, namely neurons, myocytes, 
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follicular dendritic cells, B-lymphocytes and perhaps astrocytes (Kitamoto et al. 
1991, Raeber et al. 1999, Bosque et al. 2002, Ford et al. 2002, Heikenwalder et al. 
2005, Jackson et al. 2014). 
 
1.3.3 Prion protein 
 
The human PRNP gene encodes a 253 amino acid long precursor protein. The 
mature human PrPC is 208 amino acids long and has one disulfide bond and a 
sequence for addition of a glycophosphatidylinositol (GPI) anchor. The 22 amino 
acid long N-terminal signal peptide is cotranslalionally cleaved off during synthesis 
in the endoplasmic reticulum. Once inside the endoplasmic reticulum, a 23 amino 
acid GPI anchor signal sequence is cleaved off the C-terminus during the addition of 
the GPI anchor to PrP. Then, the GPI anchor facilitates the attachment to the cell 
membrane (Stahl et al. 1990, Linden et al. 2008). The N-terminal region of PrP 
contains an octapeptide repeat region (Figure 1.3.3.1). The structure of PrP is 
mainly alpha-helical (40% alpha helical, little beta-sheet structure). The molecular 
mass of PrP is 35-36 kDa. Due to two asparagine sites the protein can have zero, 
one or two glycans, resulting in PrP appearing on western blots with a three band 
pattern (Endo et al. 1989, Linden et al. 2008). 
The pathogenic isoform, PrPSc, has the same primary sequence as PrPC, but differs 
in the secondary and tertiary structure (Linden et al. 2008). The exact structure is 
not known, but PrPSc has more beta-sheet structure (45% beta-sheet, 30%  
alpha-helical structure) which somehow makes it partially resistant to proteolysis  
(Figure 1.3.3.1, Figure 1.3.3.2) (Pan et al. 1993).  
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Figure 1.3.3.1: A. Western blot of brain homogenates of not infected (lane 1+2) and prion 
infected (lane 3+4) Syrian hamsters. Lanes 2+4 were proteinase K treated, completely 
hydrolyzing PrPC (lane 2) and generating PrP 27-30 out of PrPSc (lane 4). B. Diagrams of 
hamster Prnp gene and isoforms. (Colby and Prusiner 2011) 
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Figure 1.3.3.2: Predicted models for the PrPSc structure. A. Beta-helical model with 
proposed refolding of the N-terminus of PrP 27-30 (residues 9-177) into a beta-helical 
structure (light green). The C-terminus (residues 178-230) keeps its α-helical structure (dark 
green). B. The “beta-spiral model” predicted by molecular dynamics simulation contains a 
spiraling core of extended short beta-strand sheets. C. The “parallel in-register extended 
beta-sheet model” predicts a structure containing mainly beta-sheets. In all panels the 
corresponding motifs are indicated by the same color. (Diaz-Espinoza and Soto 2012) 
 
1.3.4 Prion replication 
 
Prions replicate by a poorly understood mechanism where PrPC converts into the 
pathogenic PrPSc. Monomeric PrPSc forms dimers, then oligomers and finally large 
aggregates and amyloids. There are two models of prion replication; the refolding 
and the seeding model (Figure 1.3.4) (Weissmann et al. 2002, Aguzzi and 
Sigurdson 2004, Weissmann 2004, Aguzzi and Calella 2009). 
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Figure 1.3.4: A. The refolding model of prion replication postulates an interaction between 
PrPSc and PrPC, which is induced to transform into more PrPSc. B. The seeding model of 
prion replication proposes that PrPC and PrPSc form an equilibrium, in which PrPC is highly in 
favor. If monomeric PrPSc aggregate, more monomeric PrPSc can be recruited. (Weissmann 
et al. 2002) 
 
The refolding or template-directed assistance model of prion replication postulates 
an interaction between PrPSc and PrPC, in which PrPC is induced by PrPSc to 
transform itself into more PrPSc. PrPC and PrPSc form in the process a heterodimer 
and PrPSc acts as a folding template. The emerging PrPSc homodimer divides into 
more folding templates (Weissmann et al. 2002, Aguzzi and Sigurdson 2004, 
Weissmann 2004, Aguzzi and Calella 2009). 
The seeding or nucleation–polymerization model of prion replication proposes that 
PrPC and PrPSc form a reversible thermodynamic equilibrium. The equilibrium would 
be shifted towards PrPC in a healthy state with low levels of PrPSc. Only if 
monomeric PrPSc aggregates, more monomeric PrPSc can be recruited for potential 
aggregation. In this case monomeric PrPSc would not be infectious, only the 
aggregated seeds would have infectivity (Weissmann et al. 2002, Aguzzi and 
Sigurdson 2004, Weissmann 2004, Aguzzi and Calella 2009). 
There was also a method invented to replicate prions in vitro, called protein 
misfolding cyclic amplification (PMCA), which works in technical sense like 
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polymerase chain reaction (PCR) does for DNA. In PMCA a small amount of 
misfolded prion protein is incubated with an excess of PrPC, so that transformation 
from PrPC in PrPSc can take place. The growing PrPSc aggregates are treated with 
ultrasound to fragment them into smaller seeds to cause more transformation. By 
repeating the cycle PrPC is rapidly transformed into misfolded prions (Saborio et al. 
2001, Saa et al. 2006).  
The rate of prion replication depends on many factors. Prion formation is inversely 
related to the incubation time length and correlates to the PrP expression level in 
the brain and the amount of PrPSc template. The PrP sequence itself is another 
factor, the more identical the sequences of PrPC and PrPSc, the faster the prion 
replication. Prion replication also depends on the present prion strain. Prion strains 
differ in incubation time and therefore also in prion formation. Reasons for these 
strain differences could be the different conformations of PrPSc, stability of PrPSc, 
targeting of PrPSc to replication competent cells and the PrPSc clearance rate (Masel 
et al. 1999, Fields et al. 2001, Aguzzi and Sigurdson 2004, Aguzzi and Calella 
2009). 
It is also discussed in prion research if an auxiliary protein or cofactor is needed for 
prion replication. There are some arguments for this hypothesis (Prusiner 1998, 
Colby and Prusiner 2011). For example, prion formation is restricted to some cell 
types, even though PrP is widely expressed (Kitamoto et al. 1991, Bosque et al. 
2002, Heikenwalder et al. 2005). Furthermore, only a few PrP expressing cell lines 
can be infected by prions (Beranger et al. 2001, Grassmann et al. 2013, Krauss and 
Vorberg 2013). Moreover, polyanions, lipids or lipid-like molecules are important 
cofactors for in vitro amplification of the infectious PrpSc (Ma 2012, Wang and Ma 
2013). Therefore PrP expression is necessary but not sufficient for prion replication 
(Giri et al. 2006). 
 
1.3.5 Prion strains, prion infectivity, neurotoxicity and species barrier 
 
Prion strains are phenotypic TSE variants causing disease with consistent 
characteristics like incubation time, pattern of PrPSc and spongiosis distributions and 
severity of spongiosis in the brain. Prion strains carry a molecular thumbprint based 
on the size of the proteinase K resistant PrPSc fragments, as detectable by western 
blot, and these differ between strains (Aguzzi et al. 2007). The different strains 
cannot be encoded by nucleic acid sequence or primary structure of the protein. 
The strain difference has to be somehow encoded by PrPSc, probably as different 
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disease related conformations (Figure 1.3.5A) (Pattison and Millson 1961, Prusiner 
1991, Aguzzi et al. 2007). These different conformations might be responsible for 
the various distinct characteristics of prion strains caused by stability of PrPSc, 
targeting of PrPSc to replication competent cells and the PrPSc clearance rate (Safar 
et al. 1998, Masel et al. 1999, Aguzzi et al. 2007, Aguzzi and Calella 2009). The 
glycosylation state of PrP could also be responsible for different prion strains, so 
that di-, mono- or unglycosylated PrP determine the structure of the emerging seeds 
and aggregates (Collinge 2005, Wiseman et al. 2005, Tuzi et al. 2008, Wiseman et 
al. 2015).  
In the process of neurodegeneration, prions appear to spread from an infected 
neuron to uninfected neurons and to other brain regions via anterograde axonal 
transport to axon terminals (Bouzamondo-Bernstein et al. 2004). Thereby, prions 
accumulate in the nervous system, which leads to neurotoxicity and 
neurodegeneration. Neurodegenerative processes include presynaptic bouton 
degeneration, dendritic atrophy, vacuolation of neurons and hypertrophy of 
astrocytes, leading finally to cell death (Jendroska et al. 1991).  
Although, prions consist of PrPSc, it is not necessarily the infectious unit that is 
neurotoxic. The infectious and / or toxic unit can contain primarily or exclusively 
PrPSc, it may be formations or intermediate products of PrPSc like oligomers or 
amyloid fibrils or even complexes with other cofactors (Prusiner 1998, Aguzzi et al. 
2007, Colby and Prusiner 2011). Also the loss of function of the misfolded PrP could 
result in neurotoxicity (Aguzzi et al. 2007). Particles with masses of 14-28 PrP 
molecules, often called oligomers, appear to have the most infectivity (Silveira et al. 
2005). However, even a monomeric, alpha-helical prion protein species can be toxic 
(Lasmezas and Zhou 2012). Therefore, the direct cause of neurotoxicity in TSEs 
remains unclear. 
Prions isolated from one species are often less infectious to other species, 
demonstrated by longer incubation times and reduced attack rates (Aguzzi et al. 
2007). This phenomenon is known as the species barrier and it depends on the 
different PrP sequences and structure of the host and the new recipient. The more 
different the PrP sequences are, the stronger the species barrier is (Aguzzi et al. 
2007). With serial passages incubation times can decrease, a phenomenon called 
adaptation. With a very potent species barrier the new inoculated host shows no 
disease phenotype and stays healthy. However, brain isolates of these healthy, 
disease resistant animals can transmit disease to new susceptible animals. So they 
act as subclinical carriers (Figure 1.3.5B) (Aguzzi et al. 2007). The species barrier 
can be reduced by very high expression levels of heterologous PrP (Sigurdson et al. 
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2006). Interestingly, even hosts from the same species can show different 
incubation times and attack rates due to certain mutations or polymorphisms of their 
Prnp gene, known as transmission barrier (Figure 1.3.5B) (Aguzzi et al. 2007). 
 
 
Figure 1.3.5: A. Different prion strains / isolates result in distinct disease phenotypes in 
identical hosts. These features persist in passages to new hosts. Strains can exhibit 
characteristic biochemical signatures because of different PrPSc conformations. B. Prions 
from one species are often less infectious to other species. This depends on different host 
PrP sequences. With serial passages incubation times decrease (adaption). With a potent 
species barrier the new inoculated host stays healthy. Brain isolates of these subclinical 
carriers can transmit disease to susceptible new hosts. Hosts from the same species can 
show different incubation times due to certain mutations or polymorphisms of the Prnp gene 
(transmission barrier). (Aguzzi et al. 2007) 
 
One example well known in the general public of a bypass of the species barrier 
was the BSE crisis in the Eighties and Nineties in Europe, especially in the United 
Kingdom. Humans developed an unusual prion disease called variant CJD from 
consuming food contaminated with BSE from diseased cattle showing the zoonotic 
potential of prions. This prion disease features a relatively short incubation time and, 
surprisingly, the victims were much younger compared to those with other prion 
diseases. Humans infected with variant CJD had a specific PRNP genotype; they 
were homozygous for methionine at codon 129 (Hill et al. 1997, Heath et al. 2010, 
Takeuchi et al. 2013). Homozygosity for methionine at codon 129 of PRNP is 
thought to be a risk factor for human prion disease, approximately 40% of the 
Caucasian population has this PRNP genotype (Ward 2000, Bishop et al. 2009). 
However, if only this genotype is susceptible to variant CJD is uncertain. The 
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incubation time of CJD caused by BSE contaminated food for other PRNP 
genotypes might just be longer (Collinge 1999, Collinge 2005). 
 
1.3.6 Prion protein function 
 
The function of endogenous PrP is still poorly understood. Earliest studies reported 
that Prnp knock-out mice are healthy with normal development and lifespan and 
without any abnormalities (Bueler et al. 1992, Manson et al. 1994a). However, more 
recent studies have shown some abnormalities. One study showed abnormal 
sleep/wake cycles and altered circadian rhythm in mice lacking PrP (Tobler et al. 
1996, Tobler et al. 1997). Another study reported deficits in long-term potentiation 
and learning (Criado et al. 2005). Also, different behavioral (decreased anxiety, 
increased locomotor and exploratory activity) and cellular abnormalities (reduced 
number of mitochondria, abnormal mitochondria, increased phagocytosis) could be 
shown (Steele et al. 2007b). 
PrP seems to have a neuroprotective function because the absence of PrP 
contributes to an increased susceptibility to oxidative stress or apoptosis (Roucou et 
al. 2004, Biasini et al. 2012). Therefore, a putative function as a regulator of 
apoptosis and also immune system / immune response was proposed (Aguzzi and 
Polymenidou 2004). Furthermore, PrP could have a function in signal transduction 
and as growth factor for axons, neurites and dendrites to support neuronal polarity 
(Chen et al. 2003, Stuermer et al. 2004, Kanaani et al. 2005). PrP was also 
described to have functions in the self-renewal of long term repopulating 
haematopoietic stem cells and as a regulator of neural precursor proliferation during 
development and neurogenesis (Steele et al. 2006, Zhang et al. 2006). A function 
as a copper transporter has been discussed since the octapeptide repeat region of 
PrP can bind copper (Hornshaw et al. 1995, Requena et al. 2001). 
 
1.3.7 Prion disease therapeutics 
 
TSEs are always fatal and no therapies exist to stop or slow the disease. For 
inherited prion diseases molecular biology enables the indentification of people at 
risk because of mutations or polymorphisms in the PRNP even decades before 
symptoms occur (Chapman et al. 1994, Spudich et al. 1995, Prusiner 1998, Fields 
et al. 2001, Colby and Prusiner 2011). Therefore, carriers of Prnp mutations would 
be ideal candidates for the development of therapies. 
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There are several ways prion diseases may be altered by developing therapeutics. 
First, reduction of PrPC levels prolongs incubation time (Bueler et al. 1993, Prusiner 
et al. 1993, Manson et al. 1994b, Safar et al. 2005a). Second, slowing down PrPSc 
formation also prolongs the incubation time (Kawasaki et al. 2007). Third, reducing 
the availability of PrPC in prion infected cells allows for clearance of prions (Enari et 
al. 2001, Peretz et al. 2001, Safar et al. 2005a). Fourth, improvement of the PrPSc 
clearance would be useful as therapy (Supattapone et al. 1999, Supattapone et al. 
2001). 
Blocking the formation of PrPSc would be one approach promising for therapeutics. 
Thus, there are many potential therapeutic targets. Indeed, many compounds 
inhibiting conversion of PrPC to PrPSc have been found (polysulfated anions, 
dextrans, Congo red dye, oligonucleotides and cyclic tetrapyrroles). But for an 
effective treatment an adequate access of the compounds to the nervous system is 
required (Fields et al. 2001, Trevitt and Collinge 2006, Sim and Caughey 2009, 
Colby and Prusiner 2011). Tricyclic derivatives of acridine, like quinacrine or 
chlorpromazine, inhibit prion formation. They can pass the blood brain barrier and 
therefore become candidates for prion disease treatment (Korth et al. 2001). 
Also, recombinant antibodies and antibody fragments are tested for prion disease 
treatment. But here the passage through the blood brain barrier remains 
problematic (Peretz et al. 2001). Another therapeutic approach is the use of RNA 
interference, a method to silence posttranscriptionally gene expression in a 
sequence-specific manner. With help of this mechanism gene expression of PrPC 
can be reduced and it could be shown that this reduction lead to neuronal rescue, 
prevention of symptoms and increased survival in prion diseased mice (Kong 2006, 
White and Mallucci 2009). However, for therapeutic approaches a better 
understanding of the mechanism of aggregation and toxicity of the disease related 
proteins is needed. 
 
1.3.8 Scrapie 
 
Scrapie, one of several TSEs in animals, was first reported in 1732 (Liberski 2012). 
It is a fatal and degenerative disease affecting the nervous system of sheep and 
goat. It is infectious and transmissible among conspecifics, but not infectious to 
humans even if humans eat infected meat of these animals (Detwiler 1992, Detwiler 
and Baylis 2003). Clinical signs of scrapie are the eponymous fleeces scraping off, 
itching sensation, lip smacking and an altered gait (Foster et al. 2001). Probable 
transmission routes are oral uptake of scrapie contaminated material, the admission 
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of scrapie material via skin lesions and the intrauterine transmission from the 
mother to the lamb (Detwiler and Baylis 2003). For scrapie, several prion stains are 
known with different incubation times and symptoms (Pattison and Millson 1961). 
The transmission of scrapie as a model disease into various animal models, 
especially rodents, has led to a better understanding of prion diseases and disease 
mechanism in the prion field (Foster et al. 2001). 
 
The mouse adapted Rocky Mountain Laboratory scrapie strain (RML) is a  
well-known and commonly used model of prion disease. RML is highly precise and, 
although it is a slowly progressing disease, all mice become terminally ill within a 
very small time frame (Di Bari et al. 2012). 
 
1.4 RiboTag 
 
RiboTag is a method to isolate cell-type-specific, ribosome associated, actively 
translated mRNA from complex tissue. This is accomplished by expressing in 
specific cell types a modified ribosome protein that carries an antibody epitope and 
incorporates into translating ribosomes (Sanz et al. 2009). In the RiboTag mice the 
genetically engineered large subunit ribosomal protein 22 (Rpl22) has a floxed 
(flanked by loxP sites) wild type terminal exon (exon 4) followed by a copy of this 
exon with three copies of the hemagglutinin (HA) epitope before the stop codon 
(Figure 1.4.1). The HA epitope tag is derived from human influenza virus 
hemagglutinin protein, corresponding to amino acids 98-106 (nucleotide sequence: 
5’-TACCCATACGATGTTCCAGATTACGCT-3’; amino acid sequence: 
YPYDVPDYA). 
When the RiboTag mouse is crossed to a Cre recombinase expressing mouse, 
expression of the epitope-tagged ribosomal protein version is activated  
(Figure 1.4.1). By using a cell-type-specific Cre recombinase expressing mouse 
(Cre driver mouse, expression of Cre recombinase under control of a  
cell-type-specific promotor), expression of the epitope-tagged ribosomal protein 
version is activated in a cell-type-specific manner (Figure 1.4.2). The RiboTag 
bearing ribosomes and the mRNAs attached to them are affinity purified by 
immunoprecipitation (IP) from crude brain homogenates and the attached mRNAs 
are then isolated for following analyses (Sanz et al. 2009). 
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Figure 1.4.1: Endogenous Rpl22 gene locus (top), engineered RiboTag mouse Rpl22 gene 
locus with floxed wild type exon 4 followed by a copy of the wild type exon 4 with 
hemagglutinin epitope tag (middle) and the RiboTag mouse after crossing to a Cre driver 
mouse (bottom). (Modified figure) (Sanz et al. 2009) 
 
 
Figure 1.4.2: Immunohistochemistry staining of 4μm thick brain sections from RiboTag mice 
crossed to Gad2-Cre mice (left) or Vglut2-Cre mice (right). Staining with anti-HA antibody 
(red) to detect cells with expression of epitope-tagged ribosomes showing the  
cell-type-specific expression in GABAergic neurons (left) or glutamatergic neurons (right) in 
cerebellum and hippocampus (counterstain: hematoxylin). (Walker Scot Jackson, AG 
Jackson, DZNE Bonn) 
 
This powerful tool accomplishes two special objectives at once. First it can capture 
mRNA from specific cell types, and second it specifically captures mRNAs that are 
being actively translated, which correlates with the proteome much better than total 
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mRNAs (Battle et al. 2015). Furthermore, since frozen tissues can be used, mRNA 
is well preserved, which can be difficult to achieve with methods that physically 
separate cells or cell bodies or other secluded cell compartments like axons or 
synapses. In addition, by engineering the mouse line the endogenous gene was 
modified and no random insertion of constructs into the mouse genome was done. 
Expression of the tagged ribosomal protein is still under control of the endogenous 
Rpl22 promotor. Therefore, the expression level and the expression locations are 
under native conditions (Sanz et al. 2009). 
 
1.5 Next generation sequencing 
 
DNA-sequencing is a biomolecular method to determine the exact order of 
nucleotides in a DNA molecule. After using the classical applications from Maxam 
and Gilbert or Sanger (Maxam and Gilbert 1977, Sanger et al. 1977),  
DNA-sequencing methods were further developed to become faster, cheaper, more 
accurate and also easier to operate as a high-throughput application. These new 
methods were called next generation sequencing and are employed for genome 
sequencing, transcriptome analysis, DNA-protein interactions and epigenome 
analysis (Mardis 2008, Pettersson et al. 2009, Liu et al. 2012). 
For our study RNA-sequencing with Illumina sequencing method was used. Illumina 
sequencing consists of three basic steps: sample preparation, DNA cluster 
generation and sequencing (Figure 1.5). 
In this method the isolated RNA is reverse transcribed into cDNA. The cDNA is 
fragmented into smaller molecules and ligated with different DNA adapter 
sequences at their ends. The adapters allow a reduced cycle amplification to add 
motifs to the cDNA fragments (sequencing primer binding sites, indices, 
complementary sequences to the flow cell oligonucleotides). The modified cDNA is 
loaded on a flow-cell where the DNA molecules can bind to the oligonucleotides on 
the plate. cDNA fragments are isothermally amplified by bridge amplification. Bridge 
amplification is repeated over and over again to build a DNA cluster on the flow cell.  
In the sequencing step the sequencing primer is extended step by step with four 
different fluorophor-coupled nucleotides. The process is called sequencing by 
synthesis. In each step the flow-cell is excited with a light source and emitted signal 
from every cluster on the flow cell is detected (Mardis 2008, Pettersson et al. 2009, 
Voelkerding et al. 2009, Liu et al. 2012). 
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Figure 1.5: Adapter-modified DNA fragments are bound on a flow-cell for Illumina 
sequencing. cDNA fragments are isothermally amplified by repeated bridge amplification to 
build DNA clusters.  Sequencing by synthesis is done with extension of the sequencing 
primer step by step with four different fluorophor-coupled nucleotides and emitted signal 
from each cluster is detected in every extension step. (Voelkerding et al. 2009)  
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2. Aim of study 
 
Specific brain regions possess specific brain cells and we hypothesize that the 
phenomenon of selective vulnerability is caused by these specific brain cells in 
these regions having unique strategies and capacities to cope with various disease 
related conformers. We also hypothesize that next to the complete proteasome the 
protein quality control machinery differs between different cell types due to different 
compilations of machinery components and clients and these differences strongly 
influence selective vulnerability. 
 
In this study infection with the RML scrapie strain was used as a model of 
neurodegenerative disease to investigate how gene expression in specific cell types 
in the mouse brain respond to an ensuing neurodegenerative disease. RML was 
chosen as our disease model because it is a well-known and commonly used 
disease model, highly precise and, although it is a slowly progressing disease, all 
mice become terminally ill within a very small time frame (Di Bari et al. 2012, 
Prusiner 2012). In addition, the hallmarks of RML infection in mice like prion 
aggregates, gliosis and spongiosis are similar to those ones occurring in human 
TSEs (Jackson et al. 2009). 
 
To analyze the response to RML infection in a cell-type-specific manner the 
advantage of the RiboTag method was used. Mice expressing the epitope-tagged 
ribosomes in astrocytes (Astro) or subsets of neurons, including glutamatergic 
(Glut), GABAergic (GABA), parvalbumin (PV) or somatostatin neurons (SST) were 
used for this study. These cell types were chosen because GABAergic neurons 
were reported to be most vulnerable in different genetic NDs (Ferrer et al. 1993, 
Guentchev et al. 1997, Guentchev et al. 1998, Guentchev et al. 1999), because 
SST and PV neurons are abundant but mostly non overlapping GABAergic neuron 
subtypes and because the glutamatergic neurons provide an informative contrast. 
Astrocytes are studied because they undergo remarkable transformations during 
NDs and identifying the molecular underpinnings of these changes will also be 
important for a fuller understanding of disease mechanisms. 
After selection of disease time points changes to gene expression were analyzed by 
next generation sequencing at a stage when clinical signs first become apparent 
and at a much earlier stage in the disease process. Neuropathological changes 
were investigated by specific IHC stainings. 
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This work gives clues into which brain cells are affected earliest and most severely 
and how they respond to the emerging disease. Investigating cell-type-specific 
mechanisms of selective vulnerability are needed for understanding NDs and 
developing therapies. A better understanding of ND mechanisms and development 
of therapies are absolutely essential because NDs currently take up a massive 
amount of money spent on health care and the ever-expanding aged population will 
amplify this problem in the future (Taylor et al. 2002, Andlin-Sobocki et al. 2005, 
Brookmeyer et al. 2007, Katsuno et al. 2012, Panegyres and Armari 2013). 
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3. Material and methods 
3.1 Biosafety and animal experimentation 
 
The major work was performed at German Center for Neurodegenerative Diseases 
(Deutsches Zentrum für Neurodegenerative Erkrankungen, DZNE, Bonn). All work 
was done under biosafety containment level 2 (S2) according to the German law 
(Gentechnikgesetz / Gentechnik-Sicherheitsverordnung). All potential contaminated 
and used equipment, reagents and material were collected, decontaminated and 
disposed following the official S2 regulations. 
The experimental procedures were approved by the North Rhine-Westphalia State 
Environment Agency for Nature, Environment and Consumer Protection 
(Landesamt für Natur, Umwelt und Verbraucherschutz Nordrhein-Westfalen, 
Recklinghausen) 
 
Reference numbers: 
84-02.04.2013.A128 
84-02.04.2013.A169 
 
3.2 Mouse lines, holding and breeding 
  
For electroencephalography (EEG) recordings and gene expression studies with the 
RiboTag method mice were bred and held at Federal Institute for Drugs and Medical 
Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn). Throughout 
the study, mice were housed in individual ventilated cages (22°C; 60% humidity) on 
a standard 12h light (06:00-18:00) / 12h dark (18:00-06:00) cycle. All mice received 
rodent laboratory pellets and drinking water ad libitum. 
For the behavioral comparison of wild type C57Bl/6N (n=24) and 129S4/SvJae 
(n=16) mice, animals were bred and held at the animal facility of Massachusetts 
Institute of Technology (MIT; Cambridge, Massachusetts, United States of 
America). 
For EEG recordings and collateral body weight measurements ten male wild type 
129S4/SvJaeJ mice were used and injected with 20µl 0.1% brain homogenate from 
either normal (NBH, n=5) or prion infected (RML; n=5) mice. 
For gene expression analysis RiboTag mice were crossed to cell-type-specific Cre 
driver lines to express HA-tagged ribosomes in specific cell types. Rtag/Vglut2-Cre 
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mice were used for glutamatergic neurons (Glut, Cre driver: Vglut2), Rtag/Gad2-Cre 
for GABAergic neurons (GABA, Cre driver: Gad2), Rtag/SST-Cre for somatostatin 
neurons (SST, Cre driver: SST), Rtag/PV-Cre for parvalbumin neurons (PV, Cre 
driver: Pvalb) and Rtag/Cnx43-CreER for astrocytes (Astro, Cre driver: Cnx43). 
Used mice were bred heterozygous for both, RiboTag and Cre recombinase  
(Rtag: floxed/wild type; Cre recombinase: +/-). Heterozygosity of RiboTag and Cre 
recombinase was checked by genotyping. Rtag/Cre mice were in a 129S4/SvJaeJ 
genetic background (>99%). For each condition (5 Rtag/Cre lines, injected with 20µl 
0.1% RML or NBH, sacrificed at 10 or 18 wpi) four mice were used (total n=80). 
 
Wild type mouse lines: 
129S4/SvJae for behavior, Rudolf Jaenisch (MIT) 
129S4/SvJaeJ for EEG (009104), Jackson Laboratory 
C57Bl/6N (B6NTac), Taconic Bioscience 
 
Genetically engineered mouse lines: 
RiboTag (B6N.129-Rpl22tm1.1Psam/J; 011029), Jackson Laboratory 
(Sanz et al. 2009) 
Vglut2-IRES-Cre (Slc17a6tm2(cre)Lowl/J ; 016963), Jackson Laboratory 
(Vong et al. 2011) 
Gad2-IRES-Cre (Gad2tm2(cre)Zjh/J; 010802), Jackson Laboratory 
(Taniguchi et al. 2011) 
SST-IRES-Cre (Ssttm2.1(cre)Zjh/J; 013044), Jackson Laboratory 
(Taniguchi et al. 2011) 
PV-Cre (B6;129P2-Pvalbtm1(cre)Arbr/J; 008069), Jackson Laboratory 
(Hippenmeyer et al. 2005) 
Cnx43-CreER, Martin Theis / Klaus Willecke (Institute of Genetics, University Bonn) 
(Eckardt et al. 2004) 
 
3.3 Genotyping 
 
The extraction of genomic DNA from mouse tail or ear tissue was done as 
described by Peter Laird and colleagues (Laird et al. 1991). To genotype the 
RiboTag and Rtag/Cre mice the PCR protocol of the original publication from 
Elisenda Sanz and colleagues was used (Sanz et al. 2009). Mice were genotyped 
for the presence of the Cre recombinase and the RiboTag allele. 
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For RiboTag genotyping the wild type PCR product is 260 bp long, the mutant PCR 
product from the floxed allele is 290 bp long. The Cre recombinase PCR product is 
324 bp long. 
The following PCR reaction was set up: 1µl genomic DNA (~ 50-100ng DNA), 2.5µl 
10x PCR buffer, 0.2µl dNTPs, 0.2µl Primer mix; 0.2µl Taq-Polymerase, add water to 
a total volume of 25µl. The following reaction conditions were used: 95°C for 2min 
followed by 30 cycles of 95°C for 30s, 65°C for 30s and 72°C for 30s. For detection 
and separation of PCR products an agarose gel electrophoresis was done. 
 
PCR primer: 
Cre For: 5’-GCATTACCGGTCGATGCAACGAGTG-3’ 
Cre Rev: 5’-GAACGCTAGAGCCTGTTTTGCACGTTC-3’ 
RiboTag For: 5’-GGGAGGCTTGCTGGATATG-3’ 
RiboTag Rev: 5’-TTTCCAGACACAGGCTAAGTACAC-3’ 
 
Buffer: 
Mouse tissue lysis buffer (100mM Tris pH = 8.5, 5mM EDTA, 0.2% SDS, 200mM 
NaCl, 0.25mg/ml proteinase K; proteinase K is added fresh before use) 
 
Equipment: 
Analog Heat Block, VWR 
BioDoc-IT Imaging System, UVP 
DNA Engine Tetrad2 Peltier Thermal Cycler, Bio-Rad 
Heraeus Pico 17 Centrifuge, Thermo Fisher Scientific 
Minicentrifuge Spectrafuge 3-1810, NeoLab 
NanoPhotometer, Implen 
PowerPac HC, Bio-Rad 
Thermomixer Compact, Eppendorf 
Vortex Genie I Touch Mixer, Scientific Industries 
 
Reagents and materials: 
100bp DNA Ladder (N3231), New England BioLabs 
10x Standard Taq Reaction Buffer (B9014), New England BioLabs 
1kb DNA Ladder (N3232), New England BioLabs 
Agarose Low EEO (A2114), AppliChem 
dNTP Set (M3015), Genaxxon Bioscience 
Gel Loading Dye Purple 6x (B7025), New England BioLabs 
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GelRed Nucleic Acid Gel Stain (41003), Biotium 
Proteinase K (P8044), Sigma-Aldrich 
TAE buffer 50x (A1691), AppliChem 
Taq DNA Polymerase (M0273), New England BioLabs 
 
3.4 Video-based behavior-recognition 
 
The video-based behavior-recognition is an automated, high resolution technology 
to analyze animal home cage behavior and detect behavior features and 
abnormalities in these animals. Six month old C57Bl/6N (n=24) and 129S4/SvJae 
(n=16) mice were used to compare these two wild type inbred mouse strains. The 
work was done by Walker Scot Jackson (AG Jackson, DZNE Bonn) at MIT. The 
method is described in the publication of Andrew Steele and colleagues (Steele et 
al. 2007a). 
 
3.5 Intracranial injections and tissue dissection 
 
Brain homogenate for intracranial injections was prepared as follows. First, 10% 
brain homogenate was made in 0.32M sucrose with a tissue grinder. Homogenate 
was sonicated twice for one minute at full power. Sonicated homogenate is 
centrifuged (1000g, 5min) and afterwards aliquoted and stored at -80C°. At the day 
of injection 10% brain homogenate aliquot was thawed and then diluted to 1% 
homogenate in phosphate-buffered saline (PBS) with 2% fetal bovine serum (FBS). 
It was treated in an ultrasound bath twice for one minute, centrifuged (1000g, 3min) 
and the supernatant transferred into a fresh reaction tube and diluted to the needed 
final concentration in PBS with 2% FBS. 
20µl 0.1% brain homogenate of normal or RML infected mice was injected into the 
right brain hemisphere at the bregmatic suture (circa 2mm away from the sagittal 
suture) of 2-4 month old RiboTag mice for gene expression studies and twelve 
month old 129S4/SvJaeJ wild type mice for EEG recordings. Mice were shortly 
anesthetized with isofluran while injected. Injection depth was 3mm starting at the 
outer mouse head skin. All injections for the same experiment (EEG or RiboTag) 
were done on the same day. An analgesic (Rimadyl) was administered within the 
next 72h according to the manufacturer’s instructions. 
RiboTag mice were sacrificed after 10 or 18 wpi by CO2 inhalation. Brains were 
removed, the two hemispheres separated, and one snap frozen for mRNA isolation 
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and the other formalin fixed for immunohistochemistry. Infectious prions in formalin 
fixed hemispheres were inactivated with formic acid prior to embedding in paraffin 
cassettes. 
In the Rtag/Cnx43-CreER mouse line Tamoxifen is needed to activate the Cre 
recombinase. Daily freshly prepared Tamoxifen (10mg/ml; 10µl/g body weight; at 3d 
every 24h; in 90% sterile sunflower oil / 10% ethanol) was intraperitoneal injected in 
this mouse line starting at one week before killing.   
 
Equipment: 
Elmasonic S10H, Elma 
Sonifier 102C, Branson 
 
Reagents and materials: 
Gibco Fetal Bovine Serum, Thermo Fisher Scientific 
Isoflurane FORENE 100%, AbbVie 
Omnifix-F Duo 25G (9161465V), B. Braun 
Rimadyl Cattle 50 mg/ml Solution, Pfizer 
Tamoxifen (T5648), Sigma-Aldrich 
Tissue Grinder (5ml), Wheaton 
 
3.6 Electroencephalogram 
 
For electroencephalogram (EEG) five RML injected mice and five NBH injected 
mice were used. The experiments and data analysis were performed by Lars 
Dittrich (AG Jackson, DZNE Bonn). 
Surgical procedure: After at least twelve and a maximum of 22 days incubation time, 
mice were implanted intraperitoneally with F20-EET transmitters (Channel 
bandwidth 1-50Hz) under isoflurane anesthesia. EEG leads were routed 
subcutaneously to the skull, placed epidurally above the left frontal cortex (AP: 1.5, 
ML: 1.5 mm from bregma, negative lead) and the right parietal cortex (AP: -2.5,  
ML: 2.0, positive lead) and fixed in place with dental acrylic. Electromyography 
(EMG) leads were anchored in the neck muscles. Mice were allowed at least two 
weeks of recovery before recordings. 
Data acquisition and analysis: Undisturbed 24h baseline recordings were performed 
in the home cages. Mice were kept in individual cages but could hear, smell and see 
at least one other mouse of the same experiment. The cages were placed in 
Material and methods 
 
36 
 
ventilated cabinets with a 12h light / 12h dark cycle. Sleep scoring and analysis was 
done as reported before (Morairty et al. 2013, Dittrich et al. 2015, Parks et al. 2016). 
EEG and EMG were recorded via telemetry using DQ ART software. Sampling 
frequencies were 500Hz. EEG low-pass filter cut off was 100Hz (in addition to the 
1Hz high pass and 50Hz low pass antialiasing filtering built in the transmitter). EEG 
and EMG recordings were scored in 10s epochs as wake, rapid eye movement 
sleep or non-rapid eye movement sleep by an expert scorer who examined the 
recordings visually using NeuroScore 3.0 software. EEG spectra were analyzed with 
a fast Fourier transform algorithm using a Hanning Window without overlap 
(NeuroScore) on all epochs without stage transition or artifact. For direct 
comparisons of EEG power spectra, power was expressed as relative power, each 
frequency bin (0.122Hz) was divided by the sum of the values between 0 and 50Hz. 
Relative theta power was calculated as the power between 5 and 10Hz (summed 
values of the respective frequency bins) divided by the sum of the values between 0 
and 50Hz. 
 
Equipment: 
AXIS 241Q Videoserver, Axis Communications 
Data Exchange Matrix, DSI 
Hair trimmer MT4640, Grundig 
Induction Chamber 1 Liter, VetEquip 
Isoflurane Vaporizer, VetEquip 
Receiver Boards PhysioTel RPC-1, DSI  
Small Animal Stereotaxic Instrument Model 900, David Kopf Instruments 
Stereomicroscope Leica M80, Leica Biosystems 
Transmitter F20-EET, DSI 
Ventilated Cabinet, Techniplast 
Video camera with Power Supply TVCCD-190COL, Monacor 
 
Reagents and materials: 
Cyanoacrylate, Loctite  
Isoflurane FORENE 100%, AbbVie 
Jet Dental Acrylic, Lang Dental  
Omnifix-F Duo 25G (9161465V), B. Braun 
PremiCron, B. Braun 
Rimadyl Cattle 50 mg/ml Solution, Pfizer 
Sugi absorbent swabs, Kettenbach 
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Supramid, B. Braun 
Surgical instruments, Fine Science Tools 
VaporGuard Activated Charcoal Filter, VetEquip 
 
3.7 Immunoprecipitation 
 
Cell-type-specific isolation of ribosome associated mRNA from Rtag/Cre mice is 
based on the publication of Elisenda Sanz and colleagues (Sanz et al. 2009). The 
original IP protocol was improved and done as follows. A frozen brain hemisphere 
was weighed and put into a tissue grinder with the corresponding volume of 
polysome buffer to prepare a 10% brain homogenate. Homogenate was prepared 
with help of a mechanical tissue grinding device (600rpm, ~30s) on ice and 
centrifuged (10000g, 10min, 4°C). Supernatant was transferred to a new reaction 
tube and used as IP input and for isolation of total RNA. For IP with magnetic beads 
pre-cleared supernatant (25µl beads and 200µl supernatant, 30min, 4°C) was first 
incubated with antibody anti-HA 12CA5 (200µl pre-cleared supernatant, 10µl 
antibody, 45min, 4°C) and this mixture then added to the magnetic beads (50µl 
beads, 1-2h, 4°C). Magnetic beads were washed three times with PBS (~500µl) 
before use and incubation steps of IP were done on a rotator. IP samples were put 
on a magnetic rack and the magnetic bead pellets were washed three times with 
high salt buffer (~500µl). Cell-type-specific mRNA was eluted from the magnetic 
beads by RLT buffer with supplemented 2-mercaptoethanol from the RNeasy Mini 
Kit (200µl, Thermomixer: 700rpm, 5-10min, RT) and afterwards isolated with this kit. 
For each supernatant two technical replicates of IP were done. Also total RNA from 
the input supernatant (200µl) was isolated in parallel. Quality and quantity of 
immunoprecipitated mRNA and total RNA isolated from the input supernatant were 
verified by Qubit Fluorometer and Agilent 2100 Bioanalyzer. 
 
Buffer: 
High salt buffer (50mM Tris pH = 7.5, 300mM KCl, 12mM MgCl2, 1% Nonidet P-40, 
1mM DTT, 100µg/ml cycloheximide; DTT and cycloheximide were added fresh 
before use) 
Polysome buffer (50mM Tris pH = 7.5, 100mM KCl, 12mM MgCl2, 1% Nonidet P-40, 
1mM DTT, 1x Protease inhibitor, 100U/ml RNAse inhibitor, 100µg/mL 
cycloheximide; DTT, Protease inhibitor, RNAse inhibitor and cycloheximide were 
added fresh before use) 
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Equipment: 
Bioanalyzer 2100, Agilent Technologies 
Centrifuge 5424R, Eppendorf 
Heraeus Pico 17 Centrifuge, Thermo Fisher Scientific 
Overhead Stirrer RZR2021, Heidolph 
Qubit 2.0 Fluorometer, Thermo Fisher Scientific 
Rotator SB2, Stuart 
Thermomixer Compact, Eppendorf 
Vortex Genie I Touch Mixer, Scientific Industries 
 
Reagents and materials: 
Agilent RNA 6000 Nano Kit, Agilent Technologies 
Agilent RNA 6000 Pico Kit, Agilent Technologies 
Anti-HA 12CA5, Roche Life Science 
Cycloheximide (C7698), Sigma-Aldrich 
Dynabeads Protein G for Immunoprecipitation (10004D), Thermo Fisher Scientific 
Magna GrIP Rack (8 well), Merck Millipore 
Qubit RNA HS Assay Kit, Thermo Fisher Scientific 
RNAase inhibitor (N8080119), Thermo Fisher Scientific 
RNeasy Mini Kit, Qiagen  
SIGMAFAST Protease Inhibitor Tablets (S8820), Sigma-Aldrich 
Tissue Grinder (5ml), Wheaton 
 
3.8 RNA-sequencing library preparation and RNA-sequencing 
 
Library preparation and RNA-sequencing was done at the DZNE in Göttingen (AG 
Bonn). 300ng of total RNA or 150ng of immunoprecipitated mRNA (higher 
concentrated IP replicate) was used for RNA-sequencing run. Each individual RNA 
sample was checked again for quality and RNA integrity number using Nanodrop 
2000 and Agilent 2100 Bioanalyzer respectively. For each condition (five Rtag/Cre 
lines, injected with RML or NBH, sacrificed at 10 or 18 wpi) we used four individual 
samples (exception: SST RML 10 wpi: n=3; PV NBH 10 wpi: n=3; Astro RML 18 
wpi: n=2). 
RNA was converted to cDNA using the Transcriptor High Fidelity cDNA synthesis 
Kit. RNA-sequencing libraries were prepared using the TruSeq RNA Sample 
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Preparation 2 Kit. The library quality was checked using an Agilent 2100 
Bioanalyzer and concentration was measured by a Qubit dsDNA HS Assay Kit and 
adjusted to 2nM before sequencing (single end, 50 bp) on a HiSeq 2000 Sequencer 
using TruSeq SR Cluster Kit 3-cBot-HS and TruSeq SBS Kit 3-HS according to the 
manufacturer’s instructions. 
 
Equipment: 
Agilent 2100 Bioanalyzer, Agilent Technologies 
HiSeq 2000 Sequencer, Illumina 
Nanodrop 2000, Thermo Fisher Scientific 
Qubit 2.0 Fluorometer, Thermo Fisher Scientific 
 
Reagents and materials: 
Qubit dsDNA HS Assay Kit, Thermo Fisher Scientific 
Transcriptor High Fidelity cDNA synthesis Kit, Roche Applied Science 
TruSeq RNA Sample Preparation 2 Kit, Illumina 
TruSeq SBS Kit 3-HS, Illumina 
TruSeq SR Cluster Kit 3-cBot-HS, Illumina 
 
3.9 RNA-sequencing data analysis 
 
RNA-sequencing data analysis was done in two different ways based on the same 
raw data from the RNA-sequencing run. One analysis was done by Vikas Bansai 
(AG Bonn, DZNE Göttingen) based on total gene reads, the other analysis was 
done by myself (Melvin Schleif, AG Jackson, DZNE Bonn) based on unique exon 
reads (UER).  
 
AG Jackson analysis: Raw RNA-Sequencing data was imported to CLC Genomics 
Workbench (7.5.2), quality checked, trimmed and mapped to the mouse reference 
genome (NCBI GRCm38.88). Trimming parameters: ambiguous trim limit = 2; 
quality trim limit = 0.05; minimum number of nucleotides in reads = 30. Mapping 
parameters: maximum number of hits for a read = 1; strand specific = both; 
similarity fraction = 0.8; length fraction = 0.9; mismatch cost = 2; insertion cost = 3; 
deletion cost = 3. Thereafter, mapped sequence data was compared to each other 
with CLC in the following manner: IP (for each cell type) vs. total RNA (pool of all 
available total RNA data) and RML vs. NBH [Treatment vs. control]. Differential 
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expression analysis was carried out using UER counts from CLC with the DESeq2 
package (1.6.3) (Love et al. 2014) in R-Project Bioconductor (3.1.2) (Dessau and 
Pipper 2008). Genes with less than five reads (baseMean) were filtered out. 
 
DESeq2 commands [XXX = file name, sample name, condition, …]: 
> datafile = system.file("Data/XXX.txt", package="XXX") 
> datafile 
> CountTable = read.table(datafile, header = TRUE, row.names=1) 
> head(CountTable) 
> samples <- data.frame(row.names=c("XXX", " XXX.1", ….), 
condition=as.factor(c("XXX", “XXX", …))) 
> samples 
> library("DESeq2") 
> CDS <- DESeqDataSetFromMatrix(countData = CountTable, colData=samples, 
design=~condition) 
> CDS <- DESeq(CDS) 
> res <- results(CDS) 
> head(res) 
> write.csv(res,file="XXX.csv") 
 
DESeq2 commands example (Glut, 10 wpi, RML vs. NBH, 4 replicates / condition): 
> datafile = system.file("Data/Glut 10 wpi.txt", package="DESeq2") 
> datafile 
[1] "C:/…/R/R-3.1.2/library/DESeq2/Data/Glut 10wpi.txt" 
> CountTable = read.table(datafile, header = TRUE, row.names=1) 
> samples <- data.frame(row.names=c("NBH","NBH.1","NBH.2","NBH.3", 
"RML","RML.1","RML.2","RML.3"), 
condition=as.factor(c("NBH","NBH","NBH","NBH", "RML","RML","RML","RML"))) 
> samples condition 
NBH  NBH 
NBH.1  NBH 
NBH.2  NBH 
NBH.3  NBH 
RML  RML 
RML.1  RML 
RML.2  RML 
RML.3  RML 
> library("DESeq2") 
> CDS <- DESeqDataSetFromMatrix(countData = CountTable, colData=samples, 
design=~condition) 
> CDS <- DESeq(CDS) 
estimating size factors 
estimating dispersions 
gene-wise dispersion estimates 
mean-dispersion relationship 
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final dispersion estimates 
fitting model and testing 
> res <- results(CDS) 
> head(res) 
log2 fold change (MAP): condition RML vs NBH  
Wald test p-value: condition RML vs NBH  
DataFrame with 6 rows and 6 columns 
BaseMean   log2FoldChange   lfcSE   stat   pvalue   padj 
<numeric>   <numeric>   <numeric>   <numeric>   <numeric>   <numeric> 
Snap25   228790.35   0.023463   0.069340   0.338372   0.735083   0.914074 
Calm1   105952.42   -0.005734   0.063530   -0.090253   0.928087   0.977285 
> write.csv(res,file="Glut 10 wpi.csv") 
 
AG Bonn analysis: Quality assessment was based on the raw reads using the 
FastQC (0.10.1) quality control tool. The sequence reads (single-end, 50 bp) were 
aligned to the mouse reference genome (mm10) with Bowtie2 (2.0.2) (Langmead 
and Salzberg 2012) using RSEM (1.2.29) (Li and Dewey 2011) with default 
parameters. First, the mouse reference genome was indexed using the Ensembl 
annotations (84.38) with rsem-prepare-reference from RSEM software. Next,  
rsem-calculate-expression was used to align the reads and quantify the gene 
abundance. Differential expression analysis was carried out using total gene read 
counts with DESeq2 package (1.12.4) (Love et al. 2014). Genes with less than five 
reads (baseMean) were filtered out and false discovery rate (padj) was recalculated 
with Benjamini-Hochberg procedure for the remaining genes. 
 
3.10 Pathway and gene ontology analysis 
 
For canonical pathway and gene ontology (GO) term analysis of differentially 
expressed genes Ingenuity Pathway Analysis (IPA, Qiagen Bioinformatics) and 
DAVID Bioinformatics Resources 6.8 (National Institute of Allergy and Infectious 
Diseases) were used (Huang et al. 2007, Huang da et al. 2009a, Huang da et al. 
2009b). 
 
3.11 Immunohistochemistry 
 
For immunohistochemistry (IHC) formalin fixed brain tissues were treated with 98% 
formic acid and then postfix for more than four days in formalin. Brains were then 
embedded in paraffin with cassettes containing both NBH and RML injected brains, 
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ensuring that controls and diseased samples are stained identically. Cassettes were 
cut into 4µm thick sections. Sections were dewaxed in xylene and rehydrated in 
graded dilutions of ethanol (each 5min). Sections stained for prion aggregates were 
further treated with 98% formic acid (3min). This step was excluded for all other 
stainings. Epitope retrieval was performed with a steamer in 0.01M citrate buffer 
(PrP: pH = 6; Iba1, GFAP: pH = 8; 30min). Endogenous peroxidase was removed 
with H2O2 treatment (3%, 5min). For PrP and GFAP staining Mouse on Mouse Elite 
Peroxidase Kit was used according to the manufacturer’s instructions. For Iba1 
staining 2,5% donkey normal serum was used for blocking (30min), followed by 
incubation with the primary antibody (30-60min), biotinylated secondary antibody 
(30min) and AB-Complex (30min). Staining of the epitope was done with DAB with 
Nickel for all stainings (5-10min). A counterstain with hematoxylin was performed 
(10s) and sections were dehydrated with graded dilutions of ethanol and xylene 
(each 5min). 
For each time point, NBH and RML infected brain sections were on the same slide 
twice and all brain sections were treated at the same time with the same solutions 
and materials. For taking IHC staining pictures a Zeiss AXIO Observer.A1 
microscope with Zen 2012 software was used. IHC staining pictures of NBH and 
RML infected brain sections were taken with the same microscope imaging 
parameters. 
 
Buffer: 
Citrate buffer (0.01M; pH = 6: 0.242g citric acid, 2.57g sodium citrate; pH = 8: 4mg 
citric acid, 2.935g sodium citrate; adjust to exact required pH with sodium 
hydroxide) 
 
Primary antibodies: 
Anti-GFAP Clone GA5  (MAB360), 1:5000, Merck Millipore 
Prion Protein Monoclonal Antibody SAF84, 1:200, Cayman Chemical 
Rabbit Anti Iba1 for ICC, 1:200, Waco 
 
Secondary antibodies: 
Biotin-SP-conjugated AffiniPure Donkey Anti-Rabbit IgG, 1:500, Jackson 
ImmunoResearch 
 
Equipment: 
Benchtop Tissue Processor Leica TP1020, Leica Biosystems 
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Flattening Table Leica HI1220, Leica Biosystems 
Microscope Zeiss AXIO Observer.A1, Carl Zeiss Microscopy 
Modular Tissue Embedding Center Leica EG1150, Leica Biosystems 
Rotary Microtome Leica RM2255, Leica Biosystems 
Steamer DG552, AEG 
Tissue-Tek Manual Slide Staining Set, Sakura Finetek 
Water Bath Leica HI1210, Leica Biosystems 
 
Reagents and materials: 
DAB Peroxidase (HRP) Substrate Kit with Nickel, Vector Laboratories 
Donkey Serum (S30), Merck Millipore 
Hematoxylin QS (H-3404), Vector Laboratories  
Menzel-Gläser Cover Slips, Thermo Fisher Scientific 
Menzel-Gläser Microscope Slides Superfrost Ultra Plus, Thermo Fisher Scientific 
Mouse on Mouse Elite Peroxidase Kit, Vector Laboratories 
Proteinase K (P8044), Sigma-Aldrich 
Richard Allan Scientific Cytoseal XYL, Thermo Fisher Scientific 
Vectastain Elite ABC HRP Kit, Vector Laboratories 
 
3.12 Polyacrylamide gel electrophoresis and western blot 
 
RiboTag IP was done like described with changes of certain parameters. Samples 
for polyacrylamide gel electrophoresis (PAGE) and western blot were collected 
during the whole procedure (inputs, supernatants, washing steps and bead 
samples). HA tagged ribosomes were eluted from the beads with 1x LDS sample 
buffer on a Thermomixer (50µl, 700rpm, 5min, RT). The other samples were also 
prepared for western blotting by adding the LDS sample buffer on a Thermomixer 
(700rpm, 5-10min, 70°C). 
Prepared PAGE samples (10-20µl) and standard protein ladder (5µl) were loaded 
on a NuPAGE 10% Bis-Tris Protein Gel and PAGE run was performed in a XCell4 
SureLock Midi-Cell Chamber with NuPAGE MES SDS Running Buffer (100-120V, 
~2-3h). Electrophoresis separated proteins from the gel were transferred to a 
nitrocellulose membrane with help of a wet tank Criterion Blotter and cooled 1x 
Transfer buffer (1 gel: 60min, 0.6A; 2 gels: 70min, 0.7A). After blotting nitrocellulose 
membrane was blocked with skim dry milk (5%/PBS, 30 min, RT) and incubated 
with anti-HA antibody (1h, RT, in 1% skim dry milk/PBS) followed by the secondary 
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antibody (1h, RT, in 1% skim dry milk/PBS). Washing steps in between and after 
second antibody incubation were performed three times with PBS (each 5min). 
Detection was done with SuperSignal West Chemiluminescent Substrate and Stella 
3200 imaging system. 
 
Primary antibodies: 
Monoclonal Anti-HA antibody clone HA-7, 1:1000, Sigma-Aldrich 
 
Secondary antibodies: 
Peroxidase AffiniPure Goat Anti-Mouse IgG (115-035-174), 1:5000, Jackson 
ImmunoResearch 
 
Buffer: 
10x Transfer buffer 10x (0.25M Tris base, 1.9M glycine) 
1x Transfer buffer (10% 10x Transfer buffer, 10% methanol) 
 
Equipment: 
Criterion Blotter, Bio-Rad 
Orbital Shaker PSU-10i, Biosan 
PowerPac HC, Bio-Rad 
STELLA 3200, Raytest 
Thermomixer Compact, Eppendorf 
VARIOMAG Magnetic Stirrer Mono Direct, Thermo Fisher Scientific 
XCell4 SureLock Midi-Cell, Invitrogen 
 
Reagents and material: 
Nitrocellulose Membrane Roll (0.2µm), Bio-Rad 
NuPAGE 10% Bis-Tris Protein Gels, Thermo Fisher Scientific 
NuPAGE LDS Sample Buffer 4x (NP0007), Thermo Fisher Scientific 
NuPAGE MES SDS Running Buffer 20x, Thermo Fisher Scientific 
Precision Plus Protein WesternC Standard Ladder (1610376), Bio-Rad 
SuperSignal West Femto Chemiluminescent Substrate, Thermo Fisher Scientific 
SuperSignal West Pico Chemiluminescent Substrate, Thermo Fisher Scientific    
Thick Blot Absorbent Filter Paper, Bio-Rad 
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3.13 Dot blot 
 
Different anti-HA antibodies in various concentrations were incubated with magnetic 
beads (50µl, 45min, RT). Supernatants were saved for dot blot analysis and  
bead-coupled antibody was eluted from the three times High salt buffer (500µl) 
washed magnetic beads with 1x LDS sample buffer on a Thermomixer (50µl, 
700rpm, 5-10min, RT). Nitrocellulose membrane with one underlying blot absorbent 
filter paper was placed into the Minifold Dot Blot system, washed three times with 
PBS, loaded with the supernatant and eluted bead samples in a 1:2 serial dilution 
and washed again tree times with PBS. Nitrocellulose membrane was blocked with 
skim dry milk (5%/PBS, 30 min, RT) and incubated with suitable secondary 
antibodies for the different loaded primary anti-HA antibodies (1h, RT). Detection 
was done with SuperSignal West Chemiluminescent Substrate and Stella 3200 
imaging system. 
 
Buffer: 
High salt buffer (50mM Tris pH = 7.5, 300mM KCl, 12mM MgCl2, 1% Nonidet P-40) 
 
Primary antibodies: 
Anti-HA 12CA5, Roche Life Science 
Covance Anti-HA.11 Epitope Tag Antibody, BioLegend 
Monoclonal Anti-HA antibody clone HA-7, Sigma-Aldrich 
Rabbit Anti-HA antibody (H6908), Sigma Aldrich 
 
Secondary antibodies: 
Goat Anti-Rabbit IgG–Peroxidase antibody (A9169), 1:500, Sigma-Aldrich 
Peroxidase AffiniPure Goat Anti-Mouse IgG (115-035-174), 1:5000, Jackson 
ImmunoResearch 
 
Equipment: 
Mini Laboratory Pump VP 86, VWR 
Minifold Dot-Blot System 96 Well, Whatman 
Orbital Shaker PSU-10i, Biosan 
STELLA 3200, Raytest 
Thermomixer Compact, Eppendorf 
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Reagents and material: 
Dynabeads Protein G for Immunoprecipitation (10004D), Thermo Fisher Scientific 
Nitrocellulose Membrane Roll (0.2µm), Bio-Rad 
NuPAGE LDS Sample Buffer 4x (NP0007), Thermo Fisher Scientific 
SuperSignal West Femto Chemiluminescent Substrate, Thermo Fisher Scientific    
SuperSignal West Pico Chemiluminescent Substrate, Thermo Fisher Scientific    
Thin Blot Absorbent Filter Paper, Bio-Rad 
 
3.14 Reverse transcription and real-time quantitative PCR 
 
Cell-type-specific mRNA and IP input total RNA was used for reverse transcription 
(RT) and real-time quantitative PCR (qPCR). To prepare complementary DNA 
(cDNA) TaqMan Reverse Transcription Reagents were used. The following reverse 
transcription reaction was set up: RNA (IP mRNA: ~10µl; total RNA: ~1µl), 5µl 10x 
RT Buffer, 3.5µl MgCl2 (25mM), 10µl dNTP mix (10mM, each 2.5mM), 2.5 
MultiScribe RT (50/µl), 2.5µl RNase inhibitor (20U/µl), 2.5µl Oligo d(T)16 primer, add 
water to a total volume of 50µl. The following reaction conditions were used: 65°C 
for 5min, 4°C for 2min, 37°C for 30min and 95°C for 5min. 
Prepared cDNA was used for qPCR on a 384-well plate using Power SYBR Green 
PCR Master Mix and a 7900HT Fast Real-Time System Cycler. One sample was 
added to the plate as triplet. The following qPCR reaction was set up: 4µl cDNA (RT 
reaction diluted to the needed amount for the qPCR plate), 6µl 2x Power SYBR 
Green PCR Master Mix, 2µl Primer mix (For + Rev primer; each 5µM), total volume 
of 12µl. The following reaction conditions were used: 50°C for 2min, 95°C for 10min 
followed by 40 cycles of 95°C for 15s and 60°C for 1min. 
For set up of the qPCR run and calculation of cycle threshold (CT) values of 
housekeeping genes and cell type marker genes provided SDS 2.4 software was 
used. Fold changes (enrichment or depletion of marker genes, IP vs. total RNA) 
were calculated from the CT values via ∆∆CT method (Livak and Schmittgen 2001). 
 
Primer - housekeeping genes: 
Actb For: 5‘-GTTACAGGAAGTCCCTCACC-3‘ 
Actb Rev: 5’-ACCAAAGCCTTCATACATCAAGT- 3’ 
Gapdh For: 5’-CAACAGGGTGGTGGACCT-3’ 
Gapdh Rev: 5’-TGTGAGGGAGATGCTCAGTG-3’ 
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HPRT For: 5’-CTCTGGTAGATTGTCGCTTATC-3’ 
HPRT Rev: 5’-CTCTTAGATGCTGTTACTGATAG-3’ 
Pgk1 For: 5’-TAGTGGCTGAGATGTGGCAC-3’ 
Pgk1 Rev: 5’-GCTGAGTCAAGAACAGTGAG-3’ 
 
Primer – neuron marker genes: 
Gap43 For: 5’-ATCCCAAGTCCAACAGTGTG-3’ 
Gap43 Rev: 5’-GGAACAGAGAGAAATAGAGAGG-3’ 
Syn1 For: 5’-CTCCTCCAGAAACCCCTC-3’ 
Syn1 Rev: 5’-GCCACTGTACGCATTACCACA-3’ 
 
Primer – glutamatergic neuron marker genes: 
Vglut1 For: 5’-GCACTTTATTCTCCTGGGTGG-3’ 
Vglut1 Rev: 5’-CAGAGACAGACACCAAGACAC-3’ 
Vglut2 For: 5’-GCTTGTGGTAGCAGTGATTTC-3’ 
Vglut2 Rev: 5’-AGTCAAGAGCACAGGACACC-3’ 
 
Primer – GABAergic neuron marker genes: 
Gad2 For: 5’-TCACCCTTTCACCCAGTCC-3’ 
Gad2 Rev: 5’-CACCTTCTCCAAGACCCTG-3’ 
Pvalb For: 5’-ATCAAGAAGGCGATAGGAGC-3’ 
Pvalb Rev: 5’-GCCAGAAGCGTCTTTGTTTC-3’ 
SST For: 5’-TGAGCAGGACGAGATGAGG-3’ 
SST Rev: 5’-TATGGGGTTTGGGGGAGAG-3’ 
Vgat For: 5’-GTCTGCGTTTCTGTCGTCC-3’ 
Vgat Rev: 5’-CGAACTTTCCCTCCCTTCC-3’ 
 
Primer – neuroglia and astrocyte marker genes: 
AldH1L1 For: 5’-TGCGGATCAAGACTGTGACT-3’ 
AldH1L1 Rev: 5’-GTGTCCTGTCACCAGCAG-3’ 
GFAP For: 5’-CGAGTCCCTAGAGCGGCA-3’ 
GFAP Rev: 5’-GCCCTCCAGCAATTTCCTG-3’ 
S100b For: 5’-GTTAGTTGTATCTTCCTTGCTCC-3’ 
S100b Rev: 5’-CAAGTTAGAAAGCCTCAAGTCC-3’ 
 
Equipment: 
7900HT Fast Real-Time System Cycler, Apllied Biosystems 
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DNA Engine Tetrad2 Peltier Thermal Cycler, Bio-Rad 
PowerPac HC, Bio-Rad 
Vortex Genie I Touch Mixer, Scientific Industries 
 
Reagents and material: 
MicroAmp Optical 384-Well Reaction Plate, Applied Biosystems 
MicroAmp Optical Adhesive Film, Applied Biosystems 
Power SYBR Green PCR Master Mix, Apllied Biosystems 
TaqMan Reverse Transcription Reagents (N8080234), Applied Biosystems 
 
3.15 Chemicals and consumable goods 
 
Used chemicals were either bought from Carl Roth or Sigma-Aldrich. Consumable 
goods like reaction tubes were ordered from Sarstedt or Eppendorf. Pipette tips for 
used Eppendorf and Gilson pipettes were produced by Nerbe Plus, Starlab and 
Eppendorf. Ready to use solutions like balanced salt solutions were purchased from 
Gibco (Thermo Fisher Scientific). Custom DNA primers were ordered from Sigma-
Aldrich. 
  
3.16 Software and web applications 
 
2100 Expert Software, Agilent Technologies 
Adobe Illustrator CS5.1, Adobe Systems 
Bowtie2 2.0.2, Ben Langmead / Steven Salzberg  
CLC Genomics Workbench 7.5.2, Qiagen Bioinformatics 
DAVID 6.8, National Institute of Allergy and Infectious Diseases 
DESeq2 1.6.3, Michael Love / Simon Anders / Wolfgang Huber 
DQ ART, DSI 
EndNote X7, Thomson Reuters 
FastQC 0.10.1, Babraham Bioinformatics 
GraphPad Prism 7, GraphPad Software 
Ingenuity Pathway Analysis, Qiagen Bioinformatics 
Mausoleum 6.4.6, Hanns-Eugen Stöffler 
Matlab R2013b, MathWorks 
Microsoft Office 2010, Microsoft 
NeuroScore 3.0, DSI 
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SPSS Statistics, IBM  
R-Project Biocunductor 3.1.2, R Foundation for Statistical Computing 
RSEM 1.2.29, Bo Li / Colin Dewey / Peng Liu 
SDS 2.4, Apllied Biosystems 
ZEN 2012, Carl Zeiss Microscopy 
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4. Results 
4.1 Selection of mouse genetic background 
 
The mouse genetic background has an influence on the activity levels of the 
animals. For our study we sought a genetic background that has a very consistent 
activity state. To determine the mouse genetic background for the RiboTag mice 
and the mice for EEG recordings data from video-based behavior-recognition were 
analyzed to detect behavior features and possible abnormalities of the commonly 
used C57Bl/6N (B6; n=24) and 129S4/SvJae (S4; n=16) inbred mouse strains 
(Figure 4.1). This work was done by Walker Scot Jackson (AG Jackson, DZNE 
Bonn) at MIT. Analyzed behavior features included distance travelled (Figure 4.1A), 
eating (Figure 4.1B), grooming (Figure 4.1C), hanging related (Figure 4.1D), 
jumping (Figure 4.1E) and sleeping (Figure 4.1F). Measurements were performed at 
an age of six months. 
 
 
Figure 4.1: Violin plots of behavior features (A. Distance travelled; B. Eating; C. Grooming; 
D. Hanging related; E. Jumping; F. Sleeping) from video-based behavior-recognition data of  
six month old C57Bl/6N (B6; n=24) and 129S4/SvJae (S4; n=16) mice. Dots represent 
individual mice. Colored dots of B6 group in the different behavior feature panels represent a 
given individual mouse. Shaded areas depict probability density estimates calculated using 
the Matlab function ksdensity. In panel E. the three B6 mice with the highest values were 
excluded as outliers from the calculation of the probability density. Vertical axis is interrupted 
in panel E. at the locations indicated by red lines. 
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The B6 inbred mouse strain shows highly variable behaviors within the group of 
individual animals, especially for distance travelled, eating, hanging related and 
jumping. Only in the B6 group are really outstanding individuals detectable for these 
behavioral features. Note that it is not consistently the same individuals that exhibit 
the highest scores across different behavioral measures. For example, one mouse 
of the B6 group travelled over 4000m within the limited confines of the animal 
holding cage while another mouse jumped for 14% of a 24h period. Therefore, the 
spread of the B6 group is not merely driven by a small number of abnormally 
behaving animals. Distribution of the two groups for grooming is similar, even B6 
mice spend more time grooming. Presumably because of the extensive instigation 
of other behaviors, B6 mice sleep a lot less. 
Such drastically different behavioral activities will clearly have an impact on 
metabolism and physiology and finally also on gene expression. Based on these 
results, to avoid a widely variable group of individual mice and thereby possible 
effects on gene expression, we decided to use the RiboTag mice in the S4 genetic 
background. 
 
4.2 Selection of disease time points 
 
After selection of the suitable mouse genetic background, disease time points for 
the gene expression analysis by next generation sequencing and the 
neuropathological analysis by IHC had to be chosen. It was planned to analyze two 
disease time points, a disease onset time point and an early preclinical time point. 
The disease onset was defined as the earliest time point in which a clinically 
relevant detectable difference between our control and RML group could be 
detected in living mice. For the preclinical time point we would pick the last time 
point at which the above sought after metric was exactly the same in both groups. 
To this end we recorded the EEG and EMG of S4 mice during wake and sleep at 
multiple time points after the RML injection as disease progressed. EEG and EMG 
recordings were performed by Lars Dittrich (AG Jackson, DZNE Bonn). Because we 
employed an EEG recording system that transmits data telemetrically the mice were 
able to roam untethered throughout the course of the experiment. Simultaneously, 
body weight of the animals as a disease marker was measured weekly during the 
experiment. Our S4-RML model consistently causes mice to become terminally ill at 
an average of 22.5 wpi within a very small time frame. 
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ANOVA tests demonstrate significant differences between the two groups in four 
measurements, theta frequency (5-10Hz) in wake (Figure 4.2A), deep slow wave 
sleep (NREM) (Figure 4.2B) and paradoxical sleep (REM) (Figure 4.2C) and body 
weight (Figure 4.2D). The significant difference detected was an increase in EEG 
theta frequency in RML injected mice starting at 16 wpi and this difference became 
stronger at 18 wpi. However, it began to decline by our last time point of 20 wpi 
(Figure 4.2A-C). Importantly, even at 20 wpi the mice appear healthy by passive 
observation. Only a trained experimenter could detect that the RML injected mice 
are not healthy by using specific tests. Thus, at 18 wpi the mice have a clinically 
relevant measurement that indicates animals are at the beginning of clinical 
disease. Therefore, 18 wpi time point was chosen as the disease onset for our 
planned analysis. 
 
 
Figure 4.2: A., B., and C. EEG data of wake (A), NREM sleep (B) and REM sleep (C) from 
normal (black) or RML (red) brain homogenate injected mice. D. Weekly percentage body 
weight change from initial weight of the same mouse cohorts. Two-factor mixed ANOVA 
tests demonstrate significant difference in all four measurements. A. F(6,48)=8.3, 
pval<0.001; B. F(6,48)=6.9, pval<0.001; C. F(6,48)=8.9, pval<0.001; D. F(14,98)=4.8, 
pval<0.001; asterisks indicate pval≤0.05 (Holm-Šídák test). 
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We determined an earlier time point by examining the evolution of differences in 
recorded EEG theta frequency and found that theta frequency for both groups is 
overlapping up to 10 wpi in disease progression. After 10 wpi the two groups slowly 
begin to separate. Therefore, 10 wpi was chosen as our pre-onset disease time 
point. The body weight of the animals is another widely used indicator for decline in 
health of diseased humans and mouse models with neurodegeneration. The two 
groups still overlap at 15 wpi (Figure 4.2D), indicating that the 10 wpi time point is 
well before clinical disease. Therefore, based on these results mice were sacrificed 
at 10 or 18 wpi and the brain dissected for the further planned analysis. 
 
 
4.3 Experimental setup  
4.3.1 Improvement of RiboTag immunoprecipitation 
 
To analyze gene expression changes caused by RML induced neurodegeneration 
in a cell-type specific manner the RiboTag method was used. At first,  
cell-type-specific isolation of ribosome associated mRNA from Rtag/Cre mice by 
RiboTag IP had to be established in our laboratory and at the beginning it was done 
as described in the original publication (Sanz et al. 2009). However, the achieved 
cell-type-specific mRNA yields and cell type specificity compared to input total RNA 
were not satisfactory. Therefore, we tested several changes to the original protocol 
including incubation times, buffer ingredients, reaction volumes, order of reaction 
steps and anti-HA antibody isolates or clones, testing each parameter one at a time. 
To verify the impact of the changed parameters yields of cell-type-specific 
immunoprecipitated mRNA (Agilent 2100 Bioanalyzer and Qubit Fluorometer) and 
the cell type specificity (RT followed by qPCR; enrichment or depletion of cell type 
marker genes) were analyzed. Western blot was used to analyze the disposition of 
the HA tagged ribosomes during the IP, for example whether the ribosomes were 
bound and remained coupled to the beads during the procedure or dispersed in the 
supernatant or washing steps. Western blot was also informative about input 
volumes and amount of magnetic beads by checking abundance of tagged 
ribosomes bound to beads versus remaining in the supernatant. Dot blot was used 
to test different antibodies, their affinity to the magnetic beads and the needed 
antibody concentration. At the end, an improved RiboTag IP protocol was 
developed and thereafter IPs were done as described in the material and method 
section for this study (Section 3.7). 
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One important example is we discontinued the use of heparin in the brain 
homogenate. Although, the addition of heparin in the polysome buffer leads to a 
higher yield of immunoprecipitated mRNA, these mRNAs are less cell-type-specific. 
The enrichment or depletion of marker genes was more significant compared to 
preparations made with heparin (data not shown). 
In detail, additional to the exclusion of heparin in the brain homogenate changes to 
the original protocol are as follows. Instead of 200U/ml RNase inhibitor only 
100U/ml was used. The reduction of RNase inhibitor to this concentration did not 
lead to any difference of yields and cell type specificity (data not shown). 
We also tested whether the order in which antibodies and beads are added to the 
supernatant affects the IPs (direct vs. indirect IP method). In the direct method from 
the original protocol antibody-coupled beads are incubated with the brain 
homogenate. In the indirect method brain homogenate is first incubated with the 
antibody and this mixture is then added to the magnetic beads. Because the indirect 
method is prone to background contamination since the magnetic beads are not 
saturated with antibody and unspecific binding of ingredients from the brain 
homogenate supernatant to the beads can occur, brain homogenates were  
pre-cleared in advance with fresh, non-reusable magnetic beads. Elimination of the 
pre-clearing step within the indirect IP method led to contaminations in the mRNA 
and therefore to less cell-type specificity (data not shown). Changing the IP from the 
direct to the indirect method with addition of a pre-clearing step of the brain 
homogenate resulted in an increase of immunoprecipitated mRNA with constant cell 
type specificity (data not shown). 
We also tested different anti-HA antibodies for our RiboTag IP. In our experiments 
anti-HA 12CA5 worked the best. Other tested antibodies led to less yields of 
immunoprecipitated mRNA even with high concentrations or did not even stay 
coupled to the beads (data not shown). The ideal antibody concentration was 
determined by a dot blot assay. The amount of anti-HA 12CA5 antibody bound to 
the beads and the amount of antibody left in the supernatant was analyzed with 
different antibody concentrations. The antibody concentration in which the beads 
were saturated with antibody but no or little antibody was left in the supernatant was 
used. This determined concentration for the anti-HA 12CA5 antibody was  
10µl / 200µl supernatant (data not shown). 
Furthermore, different IP reaction volumes were tested. In our experiment half of the 
input volume compared to the original protocol for RiboTag IP was used, so 200µl 
instead of 400µl. With less input we proportionately harvested more 
immunoprecipitated mRNA, especially for very abundant cell types (data not 
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shown). We assume that this effect is caused by oversaturated magnetic beads and 
RNA isolation columns. If higher input volumes were used we harvested more  
cell-type-specific mRNA when the material was split on two RNA isolation columns 
than loading all material on one column (data not shown). 
In addition, different incubation times were given a trial. Incubation times were tried 
to be done as short as possible to lower the risk of RNA degradation without any 
decrease in mRNA yields or less significant cell type specificity. The final developed 
procedure includes pre-clearing of supernatant for 30min, incubation of pre-cleared 
supernatant with antibody for 45min and incubation of all components together for 
1-2h. To avoid additional risk of RNA degradation most steps of the IP protocol were 
performed at 4°C. Longer incubation times or extending the IP overnight like 
described in the original protocol had no advantages in immunoprecipitated mRNA 
yields or cell type specificity (data not shown).   
In summary, our improved RiboTag IP protocol differs from the original in six ways: 
elimination of heparin, concentration of RNase inhibitor, change to indirect IP 
method with pre-clearing, use of anti-HA 12CA5 antibody, change of IP reaction 
volumes and IP reaction incubation times. 
 
4.3.2 RNA-sequencing sample generation 
  
After the selection of mouse genetic background, disease time points for planned 
analysis and improvement of the RiboTag IP, needed Rtag/Cre mice were bred to 
isolate actively translated mRNA from specific cell types of the brain to analyze 
effects on gene expression caused by intracranial RML injection (Sanz et al. 2009). 
To study the response to RML induced neurodegeneration, mice were intracranially 
injected with brain homogenate from either normal or prion infected (RML) mice. 
Homogenates were injected into the right brain hemisphere through the bregmatic 
suture (Figure 4.3.2.1C). Mice in a 129S4 genetic background expressing the 
epitope-tagged ribosomes in astrocytes (Astro, Cre driver: Cnx43) or subsets of 
neurons, including glutamatergic (Glut, Cre driver: Vglut2), GABAergic (GABA, Cre 
driver: Gad2), parvalbumin (PV, Cre driver: Pvalb) or somatostatin neurons (SST, 
Cre driver: SST) were used to study a wide range of cell types (Figure 4.3.2.1B). 
Mice were sacrificed after 10 or 18 wpi.  
To harvest cell-type-specific mRNA, dissected, frozen mouse brain tissue was 
homogenized followed by an immunoprecipitation and RNA isolation.  
Cell-type-specific mRNA and total mRNA from brain homogenate IP input were 
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analyzed by next generation sequencing (RNA-sequencing) (Figure 4.3.2.1A). 
Changes to gene expression were analyzed for the selected disease time points, at 
a stage when clinical signs first become apparent (18 wpi) and at a much earlier 
stage (10 wpi) in the disease process (Figure 4.3.2.1C). Neuropathological changes 
(microglia activation, astrogliosis, proteinase K resistant prion aggregates and 
spongiosis) were analyzed by different IHC stainings. 
  
 
Figure 4.3.2.1: Outline of experimental plan. A. Conceptual summary of the RiboTag 
method. Frozen mouse brain tissue was homogenized. Cell-type-specific, ribosome 
associated mRNA was isolated by RiboTag IP with magnetic beads and anti-HA antibody. 
Total RNA and mRNA from Cre+ cells were used for RNA-sequencing. B. Cell types to study 
and corresponding mouse lines. RiboTag mice were crossed to cell-type-specific Cre driver 
mice to express HA tagged ribosomes only in specific cell types. C. Neurodegeneration is 
induced by intracranial injections with 20μl 0.1% RML or normal brain homogenate (NBH, 
Control) into the right brain hemisphere at the bregmatic suture. 
 
Table 4.3.2.1 (total RNA samples) and table 4.3.2.2 (IP mRNA samples) list all 
samples used for RNA-sequencing with information about conditions (cell type, time 
points, NBH or RML injection, IP mRNA or total RNA) and RNA concentration 
(n=101). 300ng of total RNA or 150ng of immunoprecipitated mRNA (higher 
concentrated IP replicate) was used for RNA-sequencing. For samples under a total 
amount of 150ng RNA all available RNA material from the higher concentrated of 
the two technical IP replicates was provided for RNA-sequencing. Before  
RNA-sequencing each individual RNA sample was checked for RNA quality and 
quantity using a Qubit Fluorometer and an Agilent 2100 Bioanalyzer. At the DZNE in 
Göttingen RNA quality and quantity was again analyzed, here with help of Agilent 
2100 Bioanalyzer and Nanodrop 2000. 
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Table 4.3.2.1: Partially pooled total RNA samples with conditions (5 cell types, 2 time points, 
NBH or RML injection, RNA type) and RNA concentration for RNA-sequencing. 
Sample 
number 
Mouse 
Cell 
Type 
Time 
Point 
Injection 
RNA 
Type 
Concentration 
[ng/µl] 
5 U37, U45 Glut 10 wpi NBH total RNA 26.0 
6 U38, U39 Glut 10 wpi NBH total RNA 31.0 
11 U11, U12 Glut 10 wpi RML total RNA 51.0 
12 U13, U14 Glut 10 wpi RML total RNA 43.0 
17 U53, U54 Glut 18 wpi NBH total RNA 30.0 
18 U57, U58 Glut 18 wpi NBH total RNA 32.0 
23 U68, U69 Glut 18 wpi RML total RNA 34.0 
24 U77, U96 Glut 18 wpi RML total RNA 37.0 
46 Z27, Z29 SST 10 wpi NBH total RNA 32.0 
47 Z32, Z33 SST 10 wpi NBH total RNA 41.0 
51 Z38, Z39 SST 10 wpi RML total RNA 28.0 
52 Z24, 25 SST 10 wpi RML total RNA 52.0 
57 Z35, Z36 SST 18 wpi NBH total RNA 54.0 
58 Z37, Z42 SST 18 wpi NBH total RNA 49.0 
63 Z44, Z45 SST 18 wpi RML total RNA 38.0 
64 Z46, Z47 SST 18 wpi RML total RNA 29.0 
84 S176, S177 Astro 10 wpi NBH total RNA 33.0 
85 S179, S18 Astro 10 wpi NBH total RNA 31.0 
90 S5, S7 Astro 10 wpi RML total RNA 29.0 
91 S11, S13 Astro 10 wpi RML total RNA 35.0 
96 S16, S21 Astro 18 wpi NBH total RNA 29.0 
97 S23, S30 Astro 18 wpi NBH total RNA 47.0 
100 S45 Astro 18 wpi RML total RNA 38.0 
101 S49 Astro 18 wpi RML total RNA 23.0 
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Table 4.3.2.2: Individual IP mRNA samples with conditions (5 cell types, 2 time points, NBH 
or RML injection, RNA type) and RNA concentration for RNA-sequencing. 
Sample 
number 
Mouse 
Cell 
Type 
Time 
Point 
Injection 
RNA 
Type 
Concentration 
[ng/µl] 
1 U37 Glut 10 wpi NBH IP 19.3 
2 U45 Glut 10 wpi NBH IP 18.3 
3 U38 Glut 10 wpi NBH IP 18.1 
4 U39 Glut 10 wpi NBH IP 21.8 
7 U11 Glut 10 wpi RML IP 19.2 
8 U12 Glut 10 wpi RML IP 23.3 
9 U13 Glut 10 wpi RML IP 16.5 
10 U14 Glut 10 wpi RML IP 17.5 
13 U53 Glut 18 wpi NBH IP 18.8 
14 U54 Glut 18 wpi NBH IP 16.7 
15 U57 Glut 18 wpi NBH IP 13.8 
16 U58 Glut 18 wpi NBH IP 19.4 
19 U68 Glut 18 wpi RML IP 12.3 
20 U69 Glut 18 wpi RML IP 14.5 
21 U77 Glut 18 wpi RML IP 11.3 
22 U96 Glut 18 wpi RML IP 13.8 
25 D203 GABA 10 wpi NBH IP 33.0 
26 D204 GABA 10 wpi NBH IP 37.0 
27 D175 GABA 10 wpi NBH IP 29.3 
28 D176 GABA 10 wpi NBH IP 32.3 
29 D687 GABA 10 wpi RML IP 33.6 
30 D688 GABA 10 wpi RML IP 39.0 
32 D689 GABA 10 wpi RML IP 33.4 
33 D690 GABA 10 wpi RML IP 30.8 
34 D198 GABA 18 wpi NBH IP 7.5 
35 D213 GABA 18 wpi NBH IP 7.0 
36 D214 GABA 18 wpi NBH IP 5.1 
37 D215 GABA 18 wpi NBH IP 6.0 
38 D692 GABA 18 wpi RML IP 13.2 
39 D693 GABA 18 wpi RML IP 16.7 
40 D694 GABA 18 wpi RML IP 20.0 
41 D695 GABA 18 wpi RML IP 17.0 
42 Z27 SST 10 wpi NBH IP 2.7 
43 Z29 SST 10 wpi NBH IP 2.6 
44 Z32 SST 10 wpi NBH IP 3.2 
45 Z33 SST 10 wpi NBH IP 3.6 
48 Z39 SST 10 wpi RML IP 2.9 
49 Z24 SST 10 wpi RML IP 4.4 
50 Z25 SST 10 wpi RML IP 3.4 
53 Z35 SST 18 wpi NBH IP 2.0 
54 Z36 SST 18 wpi NBH IP 2.7 
55 Z37 SST 18 wpi NBH IP 3.3 
56 Z42 SST 18 wpi NBH IP 2.9 
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59 Z44 SST 18 wpi RML IP 3.7 
60 Z45 SST 18 wpi RML IP 5.8 
61 Z46 SST 18 wpi RML IP 3.6 
62 Z47 SST 18 wpi RML IP 5.0 
65 E190 PV 10 wpi NBH IP 14.1 
66 E191 PV 10 wpi NBH IP 15.4 
67 E192 PV 10 wpi NBH IP 17.3 
68 E674 PV 10 wpi RML IP 14.7 
69 E675 PV 10 wpi RML IP 17.6 
70 E678 PV 10 wpi RML IP 18.9 
71 E679 PV 10 wpi RML IP 13.4 
72 E208 PV 18 wpi NBH IP 5.4 
73 E211 PV 18 wpi NBH IP 7.7 
74 E223 PV 18 wpi NBH IP 6.7 
75 E224 PV 18 wpi NBH IP 5.8 
76 E677 PV 18 wpi RML IP 5.8 
77 E680 PV 18 wpi RML IP 7.1 
78 E681 PV 18 wpi RML IP 2.6 
79 E682 PV 18 wpi RML IP 2.8 
80 S176 Astro 10 wpi NBH IP 2.9 
81 S177 Astro 10 wpi NBH IP 4.0 
82 S179 Astro 10 wpi NBH IP 3.8 
83 S18 Astro 10 wpi NBH IP 4.3 
86 S5 Astro 10 wpi RML IP 2.3 
87 S7 Astro 10 wpi RML IP 4.6 
88 S11 Astro 10 wpi RML IP 3.2 
89 S13 Astro 10 wpi RML IP 2.6 
92 S16 Astro 18 wpi NBH IP 2.3 
93 S21 Astro 18 wpi NBH IP 2.6 
94 S23 Astro 18 wpi NBH IP 2.6 
95 S30 Astro 18 wpi NBH IP 2.6 
98 S45 Astro 18 wpi RML IP 3.4 
99 S49 Astro 18 wpi RML IP 2.7 
 
One representative immunoprecipitated mRNA electropherogram from Bioanalyzer 
run for each cell type, time point and NBH or RML injected sample is given in figure 
4.3.2.2 showing good RNA quality profiles. The profiles show the internal 
Bioanalyzer marker peak at 25 nucleotides, a broad hump of mRNA with different 
length and the two ribosomal RNA peaks. Thus, the RiboTag IPs and RNA isolation 
resulted in good quality RNA samples for next generation sequencing.  
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Figure 4.3.2.2: Continued on the next page. 
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Figure 4.3.2.2: Continued on the next page. 
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Figure 4.3.2.2: Agilent 2100 Bioanalyzer electropherograms for representative 
immunoprecipitated mRNA for each cell-type, time point and NBH or RML injected sample 
(horizontal axis: number of nucleotides; vertical axis. fluorescence units). The Astro 18 wpi 
panel shows important features of the RNA profile (pound (#): internal Bioanalyzer marker 
peak; arrows (): broad hump of mRNA; asterisks (*): two ribosomal RNA peaks). 
 
4.3.3 RNA-sequencing quality control 
 
To analyze the RNA-sequencing data and for differentially expressed gene (DEG) 
analysis a good quality of the RNA-sequencing run is required. Therefore, a quality 
control of the RNA-sequencing run was performed. RNA-sequencing (AG Bonn, 
DZNE Göttingen) resulted in 3,098,782,483 reads with an average of 31,000,000 
reads for each individual sequenced sample (n=101). 100% of the reads were 50 bp 
long (Figure 4.3.3.1). 99.83% of the reads had no ambiguous base content (Figure 
4.3.3.1). 72.98% of the reads had a PHRED quality score of minimum 38 (in CLC 
given maximum PHRED score = 40; low quality: ≤19; medium quality: 20-39; high 
quality: ≥40; PHRED score 38: 700,129,924 (22.59%); 39: 1,154,171,275 (37.25%); 
40: 394,711,679 (12.74%)) (Figure 4.3.3.1). The PHRED quality score is a measure 
for the quality of the identification of nucleobases of a DNA-sequencing run (base 
calling accuracy). It indicates the probability that a given base is not correctly 
detected by the sequencing machine. 
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Figure 4.3.3.1: Continued on the next page. 
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Figure 4.3.3.1: CLC Genomics Workbench lengths distribution (sequence lengths against 
percentage of sequences), ambiguous base content (percentage of ambiguous base content 
against percentage of sequences), guanine-cytosine content (percentage of  
guanine-cytosine content against percentage of sequences) and quality distribution (average 
PHRED score against percentage of sequences) of all RNA-sequencing reads.  
 
After trimming 3,085,708, 304 reads were left (99.58%). 96.84% of the reads consist 
still of 50bp (Figure 4.3.3.2). 99.99% of the remaining reads have no ambiguous 
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base content after trimming (Figure 4.3.3.2). 73.17% of the reads show a PHRED 
quality score of minimum 38 (PHRED score 38: 704,302,282 (22.82%);  
39: 1,158,107,331 (37.53%); 40: 395,648,638 (12.82%)) (Figure 4.3.3.2). Thus, the 
RNA-sequencing resulted in excellent data quality.  
 
 
Figure 4.3.3.2: Continued on the next page. 
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Figure 4.3.3.2: CLC Genomics Workbench lengths distribution (sequence lengths against 
percentage of sequences), ambiguous base content (percentage of ambiguous base content 
against percentage of sequences), guanine-cytosine content (percentage of guanine-
cytosine content against percentage of sequences) and quality distribution (average PHRED 
score against percentage of sequences) of all RNA-sequencing reads after trimming.  
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4.4 Neuropathological changes 
 
Neuropathological changes are a hallmark of NDs and are commonly used as 
indicators of disease severity in individual samples. Therefore, potential 
neuropathological changes in the RML injected RiboTag mice were studied by IHC. 
Staining with SAF84 prion protein antibody after proteinase K treatment to detect 
proteinase K resistant aggregated prions, staining with GFAP antibody to detect 
astrogliosis and staining with Iba1 antibody to detect microglia activation were done 
(Figure 4.4.1). Abnormal staining of Iba1 and GFAP are typical for NDs. Proteinase 
K resistant prion aggregates are specific for TSEs (Figure 4.4.1, Figure 4.4.2). 
These abnormal stainings are present only in the clinical disease onset time point of 
RML injected mice (18 wpi) demonstrating activated microglia, astrogliosis and 
proteinase K resistant prion aggregates in these samples. 
 
 
Figure 4.4.1: IHC staining of RML infected and control 4μm brain sections at 10 and 18 wpi 
to detect potential neuropathological changes. Staining with SAF84 prion protein antibody 
(black) after proteinase K treatment to detect aggregated prions, staining with GFAP 
antibody (black) to detect astrogliosis and staining with Iba1 antibody (black) to detect 
microglia activation (brain region: thalamus; counterstain: hematoxylin; bar: 50 µm). 
 
The Iba1 antibody stained microglia in the 18 wpi RML infected sections are 
activated cells showing swollen, truncated processes and large cell bodies. In 
contrast, the Iba1 antibody stained some microglia of controls at the 10 and 18 wpi 
time points equally well as the RML 10 wpi samples (Figure 4.4.1). These stained 
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microglia differ in their morphology, they are resting microglia with long, ramified 
processes and small cell bodies. The similar morphology of microglia in control and 
RML 10 wpi samples indicates that the 10 wpi time point is very early in disease. 
Another eponymous hallmark of TSEs, namely spongiosis, can be seen at the  
18 wpi disease time point of RML injected mice (Figure 4.4.1, Figure 4.4.2). None of 
these neuropathological changes were detected in the early time point (10 wpi), 
again confirming that these samples were well before clinical disease, or in any of 
the control samples, confirming that these mice show no neuropathological 
characteristics of prion disease like expected. In summary, neuropathological 
changes were exclusively detected in the RML infected mice at the 18 wpi disease 
time point.  
 
 
Figure 4.4.2: IHC staining of 4μm thick brain sections of RML infected mice at 18 wpi 
showing aggregated prions (SAF84 prion protein antibody staining after proteinase K 
treatment, black) and spongiosis. Spongiosis is exemplary indicated by arrows () and 
possible blood vessels are exemplary indicated by asterisks (*) for differentiation (brain 
region: thalamus; counterstain: hematoxylin; bar: 50 µm). 
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4.5 RNA-sequencing data analysis methods 
 
There are many ways to analyze next generation sequencing data (Conesa et al. 
2016). We predicted that if our results were robust, the overall results would be 
similar when using different analysis methods und we thus tried two. For both 
analysis methods the same raw reads from the same RNA-sequencing run were 
used. Moreover, for both analyses the DESeq2 package for DEG analysis was used 
because it is commonly used (Kukurba and Montgomery 2015). 
The analyses mainly differ in the expression values for the DEG analysis. The 
analysis done in Bonn (Melvin Schleif, AG Jackson, DZNE Bonn) is based on 
unique exon reads. This expression value is the number of reads that match 
uniquely to the exons including the exon-exon and exon-intron junctions. If a read 
could be matched to more than one specific gene because there are genes with 
very similar nucleotide sequences, this read would be excluded for counting of the 
expression value. The analysis done in Göttingen (Vikas Bansai, AG Bonn, DZNE 
Göttingen) is based on total gene reads. This expression value is the number of all 
the reads that are mapped to this gene (reads that map uniquely to the gene plus 
reads that match to more positions in the reference genome if parameter maximum 
number of hits for a read > 1). In the case a read would map to multiple genes, this 
read is shared between the corresponding genes based on their relative 
abundance. 
UER and total gene reads are both absolute, not normalized expression values. 
Normalization is later done by the DESeq2 package. Furthermore, the two analyses 
differ in the software and web applications used for quality control, trimming and 
mapping of the RNA-sequencing reads. In addition, the mouse reference genome 
was not exactly the same version, though they were closely related. The following 
sections describe the results received from the two different analysis methods 
based on either UER or total gene reads. 
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4.6 RNA-sequencing analysis based on unique exon reads 
 
4.6.1 Cell type specificity 
 
To analyze gene expression changes caused by RML induced neurodegeneration 
in a cell-type specific manner the immunoprecipitated mRNA has to be  
cell-type-specific. To demonstrate the specificity of the RiboTag method, enrichment 
or depletion of known cell type marker genes compared to the total RNA input was 
investigated based on unique exon reads (Figure 4.6.1). Because the comparison is 
against the total RNA input the RNA of the cell type of interest is always present in 
this sample. Thus, the more a cell type is abundant, the less is the enrichment of 
known marker genes of this cell type, but the greater the depletion of other cell type 
markers.  
As expected, mice expressing the epitope-tagged ribosomes in glutamatergic 
neurons show enrichment in glutamatergic marker genes and depletion in 
GABAergic and astrocyte marker genes. GABAergic and GABAergic subtype 
mouse lines show GABAergic marker enrichment and depletion in glutamatergic 
and astrocyte markers. The GABAergic subtypes differ like expected in expression 
pattern of their marker genes SST and Pvalb and the marker gene Homer3, a PV 
neuron marker. The astrocyte mouse line samples show enrichment in astrocyte 
marker genes. Thus, the immunoprecipitation harvested mRNA is cell-type-specific 
and cell-type-specific response of RML induced neurodegeneration can be 
analyzed. 
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4.6.2 Comparison of cell-type-specific gene expression regulation 
 
With the RiboTag system and RNA-sequencing of our samples we detected around 
14,500 – 16,000 genes to be expressed in each cell type (expression value: unique 
exon reads; expression BaseMean ≥ 5; analyzed by Melvin Schleif, AG Jackson, 
DZNE Bonn). The commonly used expression value UER is the number of reads 
that match uniquely to the exons including the exon-exon and exon-intron junctions. 
A summary of the number of genes detected for each cell type at each time point 
and the number and percentage of differentially expressed genes with chosen 
statistical cutoffs (pval<0.05 and padj<0.1) is given in table 4.6.2.1. The statistical 
values for the cutoffs are calculated by the DEseq2 package. The pval is based on a 
gene by gene t-test (Wald test). Since multiple t-tests were done the padj is 
calculated to reduce and control for false positive DEGs (Benjamini-Hochberg). 
We found that although the 18 wpi time point represented the very beginning of 
clinical disease, the gene expression changes in the mouse brain were really drastic 
with too many changes for an in-depth gene expression analysis of which cells were 
most affected and what were the most changed molecular pathways. However, 
using the statistical cutoff of padj<0.1 the 10 wpi samples were quite interesting. 
First, we found glutamatergic neurons were changing. In contrast, GABA neurons, 
PV neurons and SST neurons were unaltered. Interestingly, we found that 
astrocytes are highly altered. 
 
Table 4.6.2.1: Number of total and differentially expressed cell-type-specific genes 
(BaseMean unique exon reads ≥ 5) at 10 and 18 wpi with pval<0.05 and padj<0.1 (NBH  
vs. RML). 
Time point Cell type Genes total pval<0.05 padj<0.1 
10 wpi 
Glut 15435 1262 (8.2%) 106 (0.7%) 
GABA 15460 327 (2.1%) 2 (0.0%) 
SST 14635 163 (1.1%) 1 (0.0%) 
PV 15763 456 (2.9%) 1 (0.0%) 
Astro 15584 1417 (9.1%) 195 (1.3%) 
18 wpi 
Glut 15503 6648 (42.9%) 6414 (41.4%) 
GABA 15989 5972 (37.4%) 5681 (35.5%) 
SST 14961 5206 (34.8%) 4643 (31.0%) 
PV 15824 5176 (32.7%) 3387 (21.4%) 
Astro 14512 2195 (15.1%) 987 (6.8%) 
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To identify and quantify the directions of variability in the data sets a principal 
component analysis was done. This mathematical analysis can be used for quality 
control to identify outlying samples and shows principal causes of variation in a 
dataset. Every dot represents an individual RNA-sequencing sample. Also the 
principal component analysis with CLC Genomics Workbench based on reads per 
kilobase per million mapped reads (RPKM) values at 10 wpi indicates that 
astrocytes are the most altered cell type. The RPKM value is a normalized 
expression value, in which feature-length and library-size effects were removed. 
RPKM is the most reported RNA-sequencing expression values (Conesa et al. 
2016). All astrocyte control samples cluster very well, showing their similar gene 
expression. The RML infected samples are not clustering with the control samples, 
showing the detected gene expression changes induced by RML infection. 
However, glutamatergic neurons are relatively unchanged, similar to the GABAergic 
neurons and GABAergic subtypes. The close clustering of NBH and RML groups in 
GABAergic, somatostatin and PV neurons reflects the small number of gene 
expression changes at 10 wpi in these cell types (Figure 4.6.2.1). 
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Figure 4.6.2.1: Continued on the next page. 
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Figure 4.6.2.1: Continued on the next page. 
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Figure 4.6.2.1: CLC Genomics workbench principal component analysis with correlation 
scatter plot of the individual samples (NBH and RML) for the different cell types at 10 wpi 
(horizontal axis range (correlation 1): 0.7 - 1.1; vertical axis range (correlation 2): -0.8 - 0.4).  
 
CLC Genomics Workbench volcano plots based on RPKM values with an empirical 
analysis of differentially expressed genes (NBH vs. RML; EDGE test based on 
tagwise dispersions) is used to quickly identify changes in big data sets. Every dot 
represents a detected gene. The horizontal axis plots the 2logFC of detected genes; 
the vertical axis plots the –log10 pval. The further away a point on the horizontal 
axis is from the center (X = 0; unregulated genes), the stronger the gene is 
regulated. The higher a gene is on the vertical axis, the more significant is the gene 
regulation. The fold change is a measurement describing the quantity change 
between two values, here the expression value between the NBH and RML groups 
(=1: no change of gene expression between the groups; <1: gene down regulated 
caused by RML infection; >1: gene up regulated caused by RML infection). The fold 
change can also be given as a logarithmic value (here as 2logFC; (=0: no change of 
gene expression between the groups; <0: gene down regulated caused by RML 
infection; >0: gene up regulated caused by RML infection). 
Volcano plots show that astrocytes are highly altered. This cell type shows a high 
distribution of fold changes. A lot of these gene expression changes in astrocytes 
are also significant with a cutoff of pval 0.05 (pval 0.05 = pval -log10 1.3). Most 
DEGs of astrocytes are down regulated. GABAergic neurons and PV neurons show 
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less distribution of DEGs within fold changes and also fewer genes with pval<0.05. 
SST neurons show in the volcano plot a high distribution within fold changes. A lot 
of genes are regulated with very high or low fold changes. However, these fold 
changes are less significant compared to other cell types. Only a small number of 
genes are regulated with pval<0.05. Glutamatergic neurons show gene expression 
changes with moderate changes. However, a lot of these changes are significant. 
Most DEGs in glutamatergic neurons show an up regulation (Figure 4.6.2.2). 
 
 
Figure 4.6.2.2: Continued on the next page. 
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Figure 4.6.2.2: Continued on the next page. 
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Figure 4.6.2.2: CLC Genomics workbench volcano plots (empirical analysis of differentially 
gene expression test, NBH and RML) for the different cell types at 10 wpi (horizontal axis 
range (2logFC): -2 - 2; vertical axis range (-log10 pval): 0 - 3) 
 
Glutamatergic neurons have more up regulation within differentially expressed 
genes based on unique exon reads, whereas astrocytes show more down 
regulation within the DEGs (padj<0.1) at the 10 wpi time point (Figure 4.6.2.3A). 
Comparing glutamatergic neuron and astrocyte DEGs (padj<0.1) at the early time 
point demonstrate little overlap of differentially expressed genes between these cell 
types, showing that individual cell types respond to the same ND differently  
(Figure 4.6.2.3B, Table 4.6.2.2). 
 
 
Figure 4.6.2.3: A. Cell-type-specific up and down regulated DEGs at 10 wpi with padj<0.1. 
B. Overlap of glutamatergic neuron and astrocyte DEGs at 10 wpi with padj<0.1. 
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Table 4.6.2.2: Comparison of cell-type-specific DEGs (gene input: padj<0.1, RML vs. NBH, 
10 wpi). 
Cell type Gene count Genes 
Glut + Astro 6 Lhfpl4 Gas5 Arc Nr4a1 Rpl41 Erc1 
Glut 100 
Ctss Dusp1 Fth1 Ighm Gm15440 Kcnip2 Ormdl3 1500009C09Rik March8 
Pik3ip1 Agpat4 Ank2 Fxyd6 Mprip Taf15 Matn2 Mmd2 Rian Trpm2 Gabrb2 
Sox8 Golgb1 Kcnj2 Lamtor4 Crcp Limd2 Atp1a2 Sirt3 Scg5 Sptbn1 Lmbrd2 
Tmem50a Klf10 Fgf11 Zcchc24 Slc6a7 Nucb2 Arl4d Trib1 Snrpd2 Apol8 
BC026585 Tet2 Lin7a Cacnb4 Gsn Macf1 Rapgef3 Btg2 Zic2 Myo5a 
Aqp11 Arl2bp Lrrc61 Ppp1r9a Necab1 Plec Tmed9 Pmch Clk1 St6galnac6 
Nfrkb Sptb Gsg1l Tceal5 Serinc5 Prdm2 Snn Rasl10b Tma7 Slc25a18 
Borcs8 Mllt6 Limch1 Snrnp35 5031439G07Rik Zkscan16 Bloc1s1 Myo6 
Lamtor2 Mapk8ip2 Spry4 Zbtb18 S100a1 Tceal6 Zfp831 Tnnt2 Fkbp2 
Mcfd2 Sptbn2 Lrrc41 Etnk1 Polr2m Gm11613 Sfxn5 Nr2c2 Zmat2 Clu Amot 
Sptan1 
GABA 2 Sf3b1 Dbp 
SST 1 Lgals3 
PV 1 Hddc3 
Astro 189 
Ap2s1 Arl6ip4 Nat14 Plxnb2 Nrgn Rprml Plat Dnajc21 Arl2 Rplp2 Daam2 
Stmn3 Ndufb9 Palm Cabp1 Rpl26 Cox6a1 Elob Mrpl18 Slc25a35 Hprt 
Snx21 Atp5e Abhd8 Uqcr11 Hnrnpa3 Rps4x Ly6h Kcnh1 C130074G19Rik 
Frzb Tbcc Rps24 Rnaseh2c C1qtnf4 Tox2 Pfdn2 Jund Prr7 Eid2 Mrpl57 
Kcnj4 Gm13889 Nr2f2 Rps20 Mapre3 Myo1c Caly Gm10073 Sms Unc79 
Rpl13a Lgals3bp Tmsb10 Rps5 Calb2 1500011K16Rik Mrps12 Usmg5 
Diras1 6030419C18Rik Ccdc124 Arpc5l Ppp3ca C4b Rps19 Cox7a2l St14 
Ppp1r16a Fbxo45 Akap12 Dynll1 Fkbp8 Rps16 Sst Cltb Ccdc92 Ap1s2 
Uqcrq Gm31166 Gas2l3 Frat1 Tpgs1 Mrpl43 Rpl14 Tmem191c Krt9 Myh7 
Rps21 Epn1 Scand1 Ndufa12 Ctsd Dohh Rps29 Nbeal2 Tmem240 Znhit2 
Lsm4 Uqcc2 Abca1 Tnnt1 Smyd2 Bag1 Ccdc85b Eif5b Mcrs1 Bola2 Sncb 
Zfp871 Hmga1-rs1 Ramp3 Ndufa2 Dynll2 Abhd11os Rnf208 Stmn1 Cd9 
Hipk2 Golga4 Pcp2 Rps26 Lypla2 Mvb12a Gabarapl1 Ctxn1 Uqcr10 
Stard10 Denr Snhg8 Selenom Pigyl Itga7 Rfxap Rprm Ube2m Uchl1 Zrsr2 
Wasf1 Cycs Use1 Ndufaf8 Bola1 Tcirg1 Acbd6 Fxyd7 Polr2f Egln2 Tbr1 
Vti1b Cck Rpl28 Calm2 Lars2 Rnf123 Cox17 Rps8 Kcnh3 Camk2n2 Epha5 
Upf2 Rplp1 Cdr1 Rpl38 Coa3 Ywhah Nog Pcp4 Nhp2 Glrx5 Matk Fcor 
Plekho1 Cxx1b Sik2 Nfkbil1 Romo1 Pkig Hspbp1 Ssbp4 Pfdn5 Ubald1 Htt 
Rpl19 Gm1673 Serpina3n Zfp160 Pcsk1n Arhgdig 
 
4.6.3 Gene expression regulation in glutamatergic neurons 
 
We next wondered if specific molecular pathways or gene ontology terms were 
changed in the specific cell types caused by RML induced neurodegeneration. We 
therefore used the IPA software and the DAVID Bioinformatics Resources web 
application. The canonical pathway analysis (IPA) shows the cell-type-specific 
disease response of the individual cell types at 10 wpi (padj<0.1). The most 
prominent IPA canonical pathway in the glutamatergic neurons is  
“Sertoli Cell - Sertoli Cell Junction Signaling”, which included only spectrins 
(cytoskeletal proteins; SPTAN1, SPTB, SPTBN1 and SPTBN2). Molecular and 
cellular functions analysis shows significant changes in molecular transport, cellular 
assembly and organization, cell morphology, signaling and cell death and survival 
(Table 4.6.3.1). 
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Table 4.6.3.1: IPA top canonical pathways and molecular and cellular functions altered in 
glutamatergic neurons (gene input: padj<0.1, RML vs. NBH, 10 wpi; list filter: pval<0.05, 
molecule hits>1) 
Canonical pathway pval Overlap 
Sertoli Cell-Sertoli Cell Junction Signaling 1.40E-02 2.3% (4/172) 
Molecular and cellular functions pval Molecules 
Molecular Transport 4.74E-02 – 2.54E-05 28 
Cellular Assembly and Organization 4.92E-02 – 2.87E-05 23 
Cell Morphology 4.92E-02 – 1.06E-04 29 
Cell-To-Cell Signaling and Interaction 4.74E-02 – 3.41E-04 25 
Cell Death and Survival 4.88E-02 – 4.65E-04 26 
 
The gene ontology analysis (DAVID) resulted in even more genes associated with 
actin, actin binding and cytoskeleton. Next to cytoskeleton associated gene ontology 
terms several transport, binding and protein binding gene ontology terms are 
detectable. Many genes within the cellular compartment analysis are also 
associated to actin and cytoskeleton, but also to cell organelles and synapses 
(Table 4.6.3.2). 
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Table 4.6.3.2: DAVID top gene ontology terms (CC: Cellular compartment, BP: Biological 
process, MF: Molecular function) altered in glutamatergic neurons (gene input: padj<0.1, 
RML vs. NBH, 10 wpi; list filter: pval<0.05, molecule hits>1) 
GO GO number + GO term name pval 
CC 
GO:0043229 Intracellular organelle 
GO:0015629 Actin cytoskeleton 
GO:0043226 Organelle 
GO:0030864 Cortical actin cytoskeleton 
GO:0030863 Cortical cytoskeleton 
GO:0097458 Neuron part 
GO:0044424 Intracellular part 
GO:0045202 Synapse 
GO:0043227 Membrane-bounded organelle 
GO:0044456 Synapse part 
2.01E-07 
3.01E-07 
6.60E-07 
7.12E-07 
6.27E-06 
7.08E-06 
1.73E-05 
1.89E-05 
2.19E-05 
3.00E-05 
BP 
GO:1902578 Single-organism localization 
GO:0065008 Regulation of biological quality 
GO:0044765 Single-organism transport 
GO:0051179 Localization 
GO:0032412 Regulation of ion transmembrane transporter activity 
GO:0022898 Regulation of transmembrane transporter activity 
GO:0032409 Regulation of transporter activity 
GO:0034765 Regulation of ion transmembrane transport 
GO:0034762 Regulation of transmembrane transport 
GO:0006811 Ion transport 
1.84E-08 
1.18E-07 
1.52E-07 
1.64E-07 
3.61E-07 
4.90E-07 
8.37E-07 
2.67E-06 
4.04E-06 
5.96E-06 
MF 
GO:0003779 Actin binding 
GO:0008092 Cytoskeletal protein binding 
GO:0005200 Structural constituent of cytoskeleton 
GO:0005509 Calcium ion binding 
GO:0098641 Cadherin binding involved in cell-cell adhesion 
GO:0098632 Protein binding involved in cell-cell adhesion 
GO:0098631 Protein binding involved in cell adhesion 
GO:0045296 Cadherin binding 
GO:0030506 Ankyrin binding 
GO:0005515 Protein binding 
6.36E-07 
9.78E-05 
7.06E-04 
3.18E-03 
3.21E-03 
3.69E-03 
4.02E-03 
4.58E-03 
5.19E-03 
7.99E-03 
 
If changes of gene expression are coordinated the IPA upstream regulator analysis 
can identify the upstream transcriptional regulators responsible for the observed 
gene expression regulation. After applying this method top candidate upstream 
regulators in glutamatergic neurons are displayed in table 4.6.3.3. They are sorted 
by pval or z-score and their significantly changed target molecules within our 
statistical cutoff of padj<0.1 in the dataset are also listed. The purpose of the 
activation z score is to conclude the activation state of a predicted transcriptional 
regulator, so if the upstream regulator is activated or inhibited. If it is an activating 
regulator and the target genes are up regulated, the predicted activation state of this 
regulator is “activated”. If the target genes are down regulated the predicted 
activation state is “inhibited”. If it is an inhibiting regulator and the target genes are 
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down regulated, the predicted activation state of this regulator is “activated”. If the 
target genes are up regulated the predicted activation state is “inhibited”. 
 
Table 4.6.3.3: IPA top upstream regulators sorted by pval or activation z-score in 
glutamatergic neurons with 2logFC, predicted activation state and significantly changed 
target molecules (gene input: padj<0.1, RML vs. NBH, 10 wpi). 
Regulator 2logFC z-score Activation Target molecules 
PSEN1 0.08 0.38 --- ARC ATP1A2 CTSS DUSP1 GAS5 
ADORA2A 0.05 -1.07 --- ATP1A2 DUSP1 NR4A1 SPTBN1 
Regulator 2logFC pval Activation Target molecules 
EPB41 -0.14 4.43E-04 --- Ank2 SPTAN1 
GNB2 0.05 7.14E-04 --- ARC DUSP1 NR4A1 
GNB1 0.01 7.14E-04 --- ARC DUSP1 NR4A1 
PSEN1 0.08 9.30E-04 --- ARC ATP1A2 CTSS DUSP1 GAS5 
miR-122-5p --- 1.59E-03 --- Ank2 ATP1A2 TRIB1 
  
4.6.4 Gene expression regulation in GABAergic neurons and subtypes 
 
With the standard cutoff of padj<0.1 there are only one or two genes significantly 
changed in GABAergic neurons, SST neurons and PV neurons based on unique 
exon read analysis. Therefore, the number of DEGs is too small for an in-depth 
gene expression analysis with changed canonical pathways and gene ontology 
terms, showing that the used cutoff is very stringent to detect early changes in gene 
expression in these cell types and confirming that the 10 wpi time point is well 
before clinical disease. 
 
4.6.5 Gene expression regulation in astrocytes 
 
Astrocytes also show a cell-type-specific disease response at 10 wpi (padj<0.1). 
Actively translated mRNAs changed in this cell type are mainly down regulated 
ribosomal proteins (IPA canonical pathways: “EIF2 Signaling”, “Regulation of eIF4 
and p70S6K Signaling”, “mTOR Signaling”) and down regulated members of the 
electron transport chain (IPA canonical pathways: “Oxidative Phosphorylation”, 
“Mitochondrial Dysfunction”). Altered molecular and cellular functions are cell death 
and survival, lipid metabolism, small molecule biochemistry, gene expression and 
protein synthesis (Table 4.6.5.1). 
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Table 4.6.5.1: IPA top canonical pathways and molecular and cellular functions altered in 
astrocytes (gene input: padj<0.1, RML vs. NBH, 10 wpi; list filter: pval<0.05, molecule 
hits>1) 
Canonical pathway pval Overlap 
EIF2 Signaling 2.23E-13 9.2% (19/207) 
Oxidative Phosphorylation 3.89E-09 11.1% (11/99) 
Mitochondrial Dysfunction 5.33E-07 6.9% (11/159) 
Regulation of eIF4 and p70S6K Signaling 2.34E-06 6.7% (10/149) 
mTOR Signaling 2.01E-05 5.3% (10/190) 
Molecular and cellular functions pval Molecules 
Cell Death and Survival 4.85E-02 – 7.19E-07 46 
Lipid Metabolism 2.94E-02 – 9.73E-05 7 
Small Molecule Biochemistry 3.90E-02 – 9.73E-05 13 
Gene Expression 1.97E-02 – 1.18E-04 9 
Protein Synthesis 4.44E-02 – 5.87E-04 10 
 
The changed mRNAs of proteins building the electron transport chain are integrated 
in cytochrome c or complex I, III, IV and V. No member of complex II is significantly 
altered. All of these electron transport chain associated DEGs found by IPA are 
down regulated (Figure 4.6.5.1). The differentially expressed ribosomal proteins are 
listed in table 4.6.5.2. Moreover, all significantly changed ribosomal proteins are 
down regulated demonstrating the massive down regulation of DEGs in astrocytes.  
 
 
Figure 4.6.5.1: Electron transport chain with DEGs in astrocytes and their 2logFC in green. 
Negative 2logFCs indicate genes are all down regulated (gene input: padj<0.1, RML vs. 
NBH, 10 wpi). 
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Table 4.6.5.2: Regulated ribosomal proteins in astrocytes with 2logFC and padj (gene input: 
padj<0.1, RML vs. NBH, 10 wpi). 
Regulated ribosomal proteins 2logFC padj 
Mrpl18 -0.56 7.48E-02 
Mrps12 -0.94 2.11E-03 
Rpl13a -0.43 7.90E-02 
Rpl14 -0.54 2.89E-02 
Rpl19 -0.63 5.32E-03 
Rpl26 -0.66 2.82E-02 
Rpl28 -0.66 1.87E-02 
Rpl38 -0.72 2.57E-02 
Rpl41 -0.59 5.24E-02 
Rplp1 -0.93 3.83E-05 
Rplp2 -0.91 4.39E-06 
Rps16 -1.05 1.84E-03 
Rps19 -0.61 4.66E-02 
Rps20 -0.65 3.86E-04 
Rps21 -0.66 2.85E-02 
Rps24 -0.58 7.90E-02 
Rps26 -0.74 6.16E-03 
Rps29 -0.74 1.77E-02 
Rps4x -0.46 8.21E-02 
Rps5 -0.37 6.31E-02 
Rps8 -0.49 4.44E-02 
 
DAVID gene ontology analysis with cellular compartments, biological processes and 
molecular functions confirms the IPA results. Most gene ontology terms detected 
are associated with the down regulated ribosomal proteins and the changed genes 
of the electron transport chain (Table 4.6.5.3). 
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Table 4.6.5.3: DAVID top gene ontology terms (CC, BP and MF) altered in astrocytes (gene 
input: padj<0.1, RML vs. NBH, 10 wpi; list filter: pval<0.05, molecule hits>1) 
GO GO number + GO term name pval 
CC 
GO:0005840 Ribosome 
GO:0022626 Cytosolic ribosome 
GO:0044391 Ribosomal subunit 
GO:0044445 Cytosolic part 
GO:0030529 Intracellular ribonucleoprotein complex 
GO:1990904 Ribonucleoprotein complex 
GO:0022627 Cytosolic small ribosomal subunit 
GO:0015935 Small ribosomal subunit 
GO:0005737 Cytoplasm 
GO:0005829 Cytosol 
1.41E-16 
3.16E-15 
9.05E-15 
6.84E-12 
3.68E-10 
3.78E-10 
1.10E-09 
4.69E-09 
9.28E-09 
2.50E-08 
BP 
GO:0006412 Translation 
GO:0043043 Peptide biosynthetic process 
GO:0043604 Amide biosynthetic process 
GO:0006518 Peptide metabolic process 
GO:1901566 Organonitrogen compound biosynthetic process 
GO:1901564 Organonitrogen compound metabolic process 
GO:0043603 Cellular amide metabolic process 
GO:0044271 Cellular nitrogen compound biosynthetic process 
GO:0034641 Cellular nitrogen compound metabolic process 
GO:0044267 Cellular protein metabolic process 
2.57E-13 
5.52E-13 
1.12E-12 
8.96E-12 
9.11E-12 
1.70E-11 
1.61E-10 
4.56E-06 
8.37E-06 
8.63E-06 
MF 
GO:0003735 Structural constituent of ribosome 
GO:0005198 Structural molecule activity 
GO:0019843 rRNA binding 
GO:0003723 RNA binding 
GO:0070180 Large ribosomal subunit rRNA binding 
GO:0015078 Hydrogen ion transmembrane transporter activity 
GO:0044822 Poly(A) RNA binding 
GO:0009055 Electron carrier activity 
GO:0008092 Cytoskeletal protein binding 
GO:0016681 Oxidoreductase activity, acting on diphenols… 
3.01E-17 
6.11E-10 
8.64E-05 
8.71E-05 
2.65E-04 
3.39E-04 
7.01E-04 
7.48E-04 
8.32E-04 
1.75E-03 
 
The top upstream regulator of the IPA analysis is RICTOR (RPTOR independent 
companion of MTOR complex 2). This regulator is associated with most of the down 
regulated ribosomal proteins and most of the proteins altered in the electron 
transport chain. RICTOR itself is slightly up regulated (2logFC: 0.16065; activation 
z-score: 4.71; not significant) and it is responsible for the down regulation of these 
proteins. Therefore, IPA predicts an activation of RICTOR. Genes regulated by 
RICTOR are listed in table 4.6.5.4. 
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Table 4.6.5.4: DEGs regulated by RICTOR in astrocytes with 2logFC and padj (gene input: 
padj<0.1, RML vs. NBH, 10 wpi). 
RICTOR regulated genes 2logFC padj 
Atp5e -0.70 3.11E-02 
Cox17 -0.92 4.70E-04 
Cox6a1 -0.64 8.80E-03 
Cox7a2l -0.40 7.90E-02 
Ndufa2 -0.55 7.79E-02 
Ndufb9 -0.50 8.89E-02 
Rpl13a -0.43 7.90E-02 
Rpl14 -0.54 2.89E-02 
Rpl26 -0.66 2.82E-02 
Rpl28 -0.66 1.87E-02 
Rpl38 -0.72 2.57E-02 
Rpl41 -0.59 5.24E-02 
Rplp1 -0.93 3.83E-05 
Rplp2 -0.91 4.39E-06 
Rps19 -0.61 4.66E-02 
Rps21 -0.66 2.85E-02 
Rps24 -0.58 7.90E-02 
Rps26 -0.74 6.16E-03 
Rps29 -0.74 1.77E-02 
Rps4x -0.46 8.21E-02 
Rps5 -0.37 6.31E-02 
Rps8 -0.49 4.44E-02 
Tcirg1 0.64 7.47E-02 
Uqcr10 -0.55 8.65E-02 
Uqcr11 -0.73 7.19E-03 
Uqcrq -0.83 6.99E-03 
 
In addition to RICTOR there are other upstream regulators responsible for the gene 
expression changes in astrocytes caused by RML induced neurodegeneration. 
Table 4.6.5.5 lists other upstream regulators and their target molecules highlighted 
by activation z-score and pval. A lot of the target molecules are again ribosomal 
proteins or members of the electron transport chain. 
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Table 4.6.5.5: IPA top upstream regulators (without RICTOR) sorted by pval or activation z-
score in astrocytes with 2logFC, predicted activation and significantly changed target 
molecules (gene input: padj<0.1, RML vs. NBH, 10 wpi). 
Regulator 2logFC z-score Activation Target molecules 
RB1 0.23 -2.65 Inhibited COA3 COX17 COX6A1 MYH7 NDUFA2  TNNT1 UQCRQ 
FOXO1 0.11 -2.00 Inhibited Atp5e MRPL57 MRPS12 NDUFA12 
PAX6 0.10 -1.98 --- PALM PCSK1N SST TBR1 
NOS2 -0.05 2.00 Activated CYCS LGALS3BP MYH7 SERPINA3 
KDM5A 0.181 2.65 Activated COA3 COX17 COX6A1 MYH7 NDUFA2, TNNT1 UQCRQ 
Regulator 2logFC pval Activation Target molecules 
POLG 0.01 9.37E-10 --- COX7A2L RPL14 RPS16 RPS19 RPS24 RPS5 USE1 
RRP1B -0.01 6.89E-06 --- RPL13A RPL14 RPL19 Rplp1 RPS19 RPS26 RPS5 RPS8 
ZFHX3 -0.36 1.32E-05 --- DOHH ROMO1 Rplp1 RPLP2 SST TBR1 UQCR10 
LMX1A 0.08 1.13E-04 --- COX6A1 NDUFA2 UQCRQ 
KDM5A 0.18 1.60E-04 Activated COA3 COX17 COX6A1 MYH7 NDUFA2 TNNT1 UQCRQ 
  
4.6.6 Summary of unique exon read data analysis 
 
Using the first analysis we found that at disease onset (18 wpi) a drastic regulation 
of gene expression is detectable. To detect which cells are affected earliest and 
how they respond to the emerging disease the early disease time point (10 wpi) was 
most informative. First, we found glutamatergic neurons were changing. However, 
GABAergic neurons, PV neurons and SST neurons were unaltered. Moreover, we 
found that astrocytes are highly altered. Glutamatergic neurons have more up 
regulation within DEGs, whereas astrocytes show more down regulation within the 
DEGs. Comparison of the DEGs of the different cell types with little overlap 
demonstrate that individual cell types respond to the same RML induced 
neurodegeneration differently. Canonical pathway analysis show actively translated 
mRNAs changed in the astrocytes are mainly ribosomal proteins and members of 
the electron transport chain. Glutametergic gene ontology analysis possesses 
genes associated to actin, actin binding, cytoskeleton, cellular transport and 
signaling. 
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4.7 RNA-sequencing analysis based on total gene reads 
 
4.7.1 Cell type specificity 
 
To demonstrate the specificity of the RiboTag method and the resulting 
immunoprecipitated cell-type-specific mRNA, enrichment or depletion of known cell 
type marker genes compared to the total RNA was also investigated for the second 
next generation sequencing analysis (Figure 4.7.1). This analysis was based on 
total gene read counts of the RNA-sequencing analysis done in Göttingen (Vikas 
Bansai, AG Bonn, DZNE Göttingen). Once again, the total gene read data analysis 
shows that immunoprecipitated mRNA is cell-type-specific. Moreover, results of 
both methods to analyze cell type specificity are highly similar. 
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4.7.2 Comparison of cell-type-specific gene expression regulation 
 
With RNA-sequencing analysis based on total gene reads we detected around 
17,000 – 18,000 genes expressed in each brain cell type (expression value: total 
gene reads; expression BaseMean ≥ 5; analyzed by Vikas Bansai, AG Bonn, DZNE 
Göttingen). A summary of the number of genes detected for each cell type at each 
time point and the number and percentage of differentially expressed genes 
(padj<0.1) is given in figure 4.7.2A. 
Gene expression changes based on total gene reads at the 18 wpi time point in the 
mouse brain were still drastic with too many changes for an in-depth gene 
expression analysis. At the 10 wpi time point we found glutamatergic and 
GABAergic neurons were changing. Again, PV neurons and SST neurons were 
unaltered. Astrocytes were again highly altered. 
Glutamatergic neurons had more up regulation within differentially expressed 
genes, whereas GABAergic neurons and astrocytes had more down regulation 
within the differentially expressed genes (padj<0.1) at the 10 wpi time point  
(Figure 4.7.2B). Comparing the differentially expressed genes (padj<0.1) of the 
different cell types at the early time point demonstrate again little overlap of 
differentially expressed genes between the lines, showing that individual cell types 
respond to the same ND differently (Figure 4.7.2C). Also the canonical pathway 
analysis (IPA) shows the cell-type-specific disease response of the individual cell 
types (Figure 4.7.2D). 
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Figure 4.7.2: A. Number of total (base mean reads ≥ 5) and differentially expressed  
cell-type-specific genes at 10 and 18 wpi with padj<0.1 (NBH vs. RML). B. Up and down 
regulated genes at 10 wpi with padj<0.1. C. Overlap of regulated genes within different cell 
types at 10 wpi with padj<0.1. D. IPA heatmap of top hits (-log(pval)) of canonical pathways 
regulated in the different cell types at 10 wpi. 
 
4.7.3 Gene expression regulation in glutamatergic neurons 
 
The most prominent IPA canonical pathway in the glutametergic neurons was again 
“Sertoli Cell – Sertoli Cell Junction Signaling” with the included spectrins at 10 wpi. 
Furthermore, the IPA molecular and cellular functions “Cellular Assembly and 
Organization” and “Cell-To-Cell Signaling and Interactions” were revealed. 
DAVID gene ontology analysis revealed again genes associated with actin, 
cytoskeleton, binding, protein binding and genes localized at organelles and 
synapses. However, with total gene read analysis no transport gene ontology terms 
are detectable. Instead, gene ontology terms associated with transcription, 
transcription factors and nervous system development were revealed. DEGs in 
glutamatergic neurons are displayed in table 4.7.3.  
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Table 4.7.3: DAVID gene ontology categories altered in glutamatergic neurons with included 
genes and their 2logFC. Red colored box indicates up regulation, green colored box 
indicates down regulation (gene input: padj<0.1, RML vs. NBH, 10 wpi). 
Genes 2logFC 
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ARC 0.50 X X X X 
ARL4D 0.48 X 
BTG2 0.39 X X X 
C4B 0.42 X X 
CLK1 0.39 X 
DLG1 -0.25 X X X 
DUSP1 0.50 X 
ETV1 -0.36 X X X 
FZD7 -0.34 X 
GABRB2 -0.47 X X X 
GFAP 0.58 X X X 
GSN 0.40 X X X 
HNRNPLL -0.31 X 
LIMCH1 0.48 X X 
MAPK8IP2 0.32 X X X X 
MPRIP 0.35 X X 
NECAB1 -0.31 X 
NR2C2 -0.44 X X X 
NR4A1 0.83 X X 
PAX6 -0.31 X X X 
PCDHGB2 -0.42 X 
PPP1R9A 0.43 X X X 
RGS4 -0.24 X 
RPS28 0.35 X 
SIRT3 0.27 X 
SOX8 0.40 X X X 
SPTAN1 0.37 X X 
SPTB 0.36 X X 
SPTBN1 0.54 X X X 
SPTBN2 0.46 X X X X 
TSHZ2 -0.42 X X 
ZBTB18 -0.28 X X 
ZIC1 -0.33 X X X 
ZIC2 -0.37 X X X 
ZXDB -0.37 X X 
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4.7.4 Gene expression regulation in GABAergic neurons and subtypes 
 
Analysis based on total gene reads shows changes in genes involved in the IPA 
canonical pathway “Circadian Rhythm Signaling” in GABAergic neurons at 10 wpi 
(Figure 4.7.4). All these circadian rhythm genes are known to be involved in 
oxidative stress response (Musiek et al. 2013, Mendez et al. 2016, Musiek and 
Holtzman 2016). With a less stringent cutoff the canonical pathway can also be 
found in the DEG analysis based on unique exon reads. The order of regulated 
genes is similar when sorted by pval and padj. However, the absolute calculated 
values for statistics do not pass our stringent cutoff (padj<0.1) in the UER analysis. 
Nonetheless, the similarities of the results from both analysis methods are clear. 
 
 
Figure 4.7.4: Regulation of DEGs involved in circadian rhythm and oxidative stress 
response in GABAergic neurons und their 2logFC based on total gene reads. Green genes 
are down regulated, red genes are up regulated and black genes are not significantly 
regulated (gene input: padj<0.1, RML vs. NBH, 10 wpi). 
 
The complexes of BMAL1/Clock or BMAL1/NPAS2 function as transcription factors. 
They drive expression of circadian clock genes and redox genes (Figure 4.7.4). All 
genes inhibiting these transcription factors are down regulated. BMAL1 itself is up 
regulated. USP2, responsible for the transport of PER1 to the nucleus is also down 
regulated. Therefore, even less PER1 is transferred into the nucleus to inhibit 
transcription of target genes. Only VIP, leading to more expression of PER1, is up 
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regulated. However, VIP functions transcellularly and its increased gene expression 
may come from healthy cells attempting to regulate the circadian clock pathway in 
sick cells. In addition, VIP has more cellular functions and is involved in other 
pathways. Surprisingly, with activation of these BMAL1 associated transcription 
factor complexes, the target genes themself are not up regulated. Analyzed redox 
genes are unchanged or, like DBP, significantly down regulated. 
 
4.7.5 Gene expression regulation in astrocytes 
 
Actively translated mRNAs changed at 10 wpi in the astrocytes are again mainly 
down regulated ribosomal proteins (pathways: “EIF2 Signaling”, “Regulation of eIF4 
and p70S6K Signaling”, “mTOR Signaling”) and down regulated members of the 
electron transport chain (pathways: “Oxidative Phosphorylation”, “Mitochondrial 
Dysfunction”) similar to the results of the unique exon reads analysis. The changed 
mRNAs of proteins building the electron transport chain are integrated again in 
cytochrome c or complex I, III, IV and V and the DEGs of both analysis are highly 
overlapping (Figure 4.7.5). However, non-overlapping DEGs in the UER analysis 
were close to but not within our stringent statistical cutoff. This is also true for 
differentially expressed ribosomal proteins. A comparison of changed ribosomal 
proteins in astrocytes caused by RML with the two analyses is shown in table 4.7.5. 
The top upstream regulator in the IPA analysis is again RICTOR with a predicted 
activation. 
 
 
Figure 4.7.5: Electron transport chain with DEGs in astrocytes und their 2logFC based on 
total gene reads in green. Negative 2logFCs indicate genes are all down regulated (gene 
input: padj<0.1, RML vs. NBH, 10 wpi). 
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Table 4.7.5: Comparison of regulated ribosomal proteins in astrocytes between the two 
analysis (gene input: padj<0.1, RML vs. NBH, 10 wpi). 
Analysis Gene count Ribosomal proteins 
UER + Total 
gene reads 16 
Rpl38 Mrps12 Rps26 Rpl14 Rps16 Rplp2 Rps21 Rps8 Rpl13a Rps19 
Mrpl18 Rps29 Rpl41 Rplp1 Rps24 Rps20 
UER 5 Rpl28 Rps4x Rpl26 Rpl19 Rps5 
Total gene 
reads 11 
Rpl35 Rps25 Rpl36 Rpl34-ps1 Rpl10a Rpl13 Rpl24 Rps27a Rpl37rt 
Rpl9 Rpl11 
 
4.7.6 Summary of total gene read data analysis 
 
Using the second analysis we found gene expression changes similar to the first 
analysis based on unique exon reads except for GABAergic neurons. To detect 
which cells are affected earliest and how they respond to the emerging disease the 
early disease time point (10 wpi) was again chosen for analysis. The gene 
expression changes of the 18 wpi time point were too drastic. First, we found 
glutamatergic neurons and GABAergic neurons were changing. However, PV 
neurons and SST neurons were unaltered. Moreover, we found that astrocytes are 
highly altered. Glutamatergic neurons have again more up regulation within DEGs, 
whereas GABAergic neurons and astrocytes show more down regulation within the 
DEGs. Comparison of the DEGs of the different cell types with little overlap 
demonstrate that individual cell types respond to the same RML induced 
neurodegeneration differently. 
Canonical pathway analysis shows actively translated mRNAs changed in the 
astrocytes are mainly ribosomal proteins and members of the electron transport 
chain. Glutametergic gene ontology analysis possesses genes associated with 
actin, actin binding, cytoskeleton, signaling and transcription. GABAergic neurons 
show changes in genes involved in circadian rhythm signaling. All these circadian 
rhythm genes are also known to be involved in oxidative stress response (Musiek et 
al. 2013, Mendez et al. 2016, Musiek and Holtzman 2016). 
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5. Discussion 
 
Why neurodegenerative diseases target specific brain regions is poorly understood. 
We hypothesize that this selective vulnerability is caused by specific brain cells in 
these regions having unique strategies and capacities to cope with various disease 
related protein conformers that ultimately fail. 
To study the phenomenon of selective vulnerability of NDs and how specific cell 
types in the mouse brain respond to a neurodegenerative disease, prion infection 
with RML scrapie strain was used in this study as a model of neurodegenerative 
disease. RML infection was combined with the RiboTag method to isolate ribosome 
associated mRNA from specific brain cell types for gene expression analysis. Mice 
expressing the epitope-tagged ribosomes specifically in astrocytes or subsets of 
neurons, including glutamatergic, GABAergic, parvalbumin and somatostatin 
neurons, were injected with brain homogenate from either normal or prion infected 
mice. Changes to gene expression were analyzed by next generation sequencing at 
disease onset and at a preclinical time point in the disease process. 
Neuropathological changes in the brain were analyzed with several ND typical IHC 
stainings. This study was performed to give clues into which cells are affected 
earliest and how they respond to the emerging disease. 
 
5.1 Selection of a disease model 
 
5.1.1 RML as a model of neurodegenerative prion disease 
 
An advantage of studying prion disease in mice is its high precision in regards to 
time to clinical illness and the neuropathological changes. The transmission of 
scrapie as a model of prion disease into various animal models, especially rodents, 
has led to a better understanding of prion diseases and disease mechanism in the 
prion field (Foster et al. 2001). The mouse adapted RML scrapie strain is a  
well-known and commonly used model of prion disease. RML is highly precise and, 
although it is a slowly progressing disease, all mice become terminally ill within a 
very small time frame (Di Bari et al. 2012). Therefore, RML infection as a model of 
neurodegenerative prion disease was chosen in our study. In our laboratory the  
S4-RML model showed behavioral changes around 18 wpi and was terminally down 
around 22.5 wpi.  
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5.1.2 Selection of S4 genetic background 
 
The advantage of high precision in regards to the clinical disease time course and 
the neuropathological changes in prion diseases could be compromised if changes 
to gene regulation unrelated to the ongoing disease process occur. Two major 
contributors to the gene regulation changes in normal mice are circadian rhythm 
and activity levels. To control for circadian rhythm mice were always killed at the 
same time of the day (12:00-13:00). To control for activity levels we sought a 
genetic background that has a very consistent activity state. To this end, behavioral 
features of two common used inbred mouse strains were studied, B6 and S4 from 
archived data (Section 4.1). The B6 inbred mouse strain showed more penetrance 
of variable behavior within the group of individual animals. Importantly, it is not 
consistently the same individuals that exhibit the highest scores across different 
behavioral measures. Therefore, the spread of the B6 group is not merely driven by 
a small number of abnormally behaving animals. Based on these results, to avoid a 
widely variable group of individual mice and thereby possible effects on gene 
expression, we decided to use the RiboTag mice in the S4 genetic background. Of 
course, for other studies the B6 strain or other available inbred mouse strains might 
be the better choice. All inbred mouse strains have special features and differ in 
their genotype and phenotype, giving benefits for certain research questions 
(Crawley et al. 1997, Bothe et al. 2005, Casellas 2011). However, the high number 
of abnormally behaving individuals in the B6 group was a criterion for exclusion of 
the B6 genetic background for our study to avoid gene expression changes because 
of widely variable activity levels.  
 
5.1.3 Selection of 10 and 18 wpi disease time points 
 
It was planned to analyze two disease time points, a disease onset time point and 
an early preclinical time point (Section 4.2). The disease onset was defined as the 
earliest time point in which a clinically relevant detectable difference between our 
control and RML groups could be detected in living mice. We found that a great 
biomarker was a significant increase of theta frequency in wake, deep slow wave 
sleep and paradoxical sleep in RML injected mice starting at 16 wpi and becoming 
stronger at 18 wpi. Thus, 18 wpi time point was chosen as the disease onset. 
For the preclinical time point the last time point at which EEG theta power was 
exactly the same in both groups was picked. By examining the evolution of 
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differences in recorded EEG theta frequency we found that theta frequency for both 
groups is overlapping until 10 wpi, after which the two groups slowly begin to 
separate. Therefore, 10 wpi was chosen as our preclinical disease time point. In 
retrospect, it would have been interesting to have analyzed more disease time 
points, especially with regard to the drastic gene expression regulation at the 18 wpi 
time point with too many changes for an in-depth gene expression analysis. 
Nonetheless, at the outset of the project it was unknown if the RiboTag method 
could provide any useful insight into mechanisms of NDs. This project clearly shows 
it does. This insight into mechanisms of NDs and selective vulnerability is needed to 
develop therapies. If these therapies should be able to stop or slow the disease 
progress, it is important to identify the disease at an early stage and to understand 
what happens at the very beginning of the disease. Therefore, an early disease time 
point, even before clinical disease, is important for identification of these early 
disease changes, finding biomarkers and eventually therapies. Although, the 18 wpi 
time point represents the very beginning of clinical disease, neuropathological 
changes and really drastic changes in gene expression were detectable. Thus, at 
this time point the disease would be difficult to treat. 
 
5.2 Neuropathological changes 
 
Neuropathological changes in the RML injected RiboTag mice were studied by IHC 
stainings with Iba1, GFAP and SAF84 prion protein antibodies (Section 4.4). 
Abnormal staining of Iba1 and GFAP could be detected at 18 wpi in RML infected 
brains, detecting ongoing astrogliosis and activated microglia. These abnormal Iba1 
and GFAP stainings are typical for NDs, showing that these brains are abnormal 
and are developing a neurodegenerative disease already at this disease onset time 
point (18 wpi). The similar morphology of microglia stained in control and RML  
10 wpi samples indicates that the 10 wpi time point is very early in disease. These 
stained microglia are not activated cells. They are resting microglia with long, 
ramified processes and small cell bodies. 
Proteinase K resistant prion aggregates are specific for TSEs and could also be 
detected at the 18 wpi time point in RML infected mice, again confirming that these 
mice are abnormal and developing a neurodegenerative prion disease. Also 
spongiosis, another hallmark of prion diseases, was detectable in the 18 wpi time 
point of RML infected mice. These results demonstrate that at disease onset time 
point (18 wpi) the brain has detectable neurophatological changes, namely activated 
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microglia, astrogliosis, proteinase K resistant prion aggregates and spongiosis 
showing that these animals are clearly diseased. None of these neuropathological 
changes were detected in the control groups and in the 10 wpi RML group, 
confirming that the 10 wpi time point is well before clinical disease and that these 
samples show no neuropathological characteristics of prion disease. 
These results also show that the intracranial injections were successfully performed 
and that infectious material was present in the injected RML brain homogenate to 
inoculate prions into the mouse brains of the RML group leading to a mouse 
adapted scrapie infection. Because control group animals show no hallmarks of 
prion disease, injections of NBH worked as expected and the disease was not 
simply an adverse reaction to foreign brain homogenate invading the immune 
privileged brain. These results also show that gene expression changes are 
detectable much earlier in the emerging disease than neuropathological changes 
and neurodegeneration. 
 
5.3 Quality of RNA samples and RNA-sequencing run 
 
To analyze the RNA-sequencing data and for DEG analysis a good quality of the 
RNA samples and the RNA-sequencing run is required. After purification each 
individual RNA sample was checked for RNA quality and quantity using a Qubit 
Fluorometer, an Agilent 2100 Bioanalyzer and a Nanodrop 2000. Bioanalyzer 
electropherograms from samples later used for RNA-sequencing showed the 
expected RNA quality profiles with internal Bioanalyzer marker peak,  broad hump 
of mRNA and the two ribosomal RNA peaks, confirming that our improved RiboTag 
IP protocol and RNA isolation of immunoprecipitated mRNA and isolation of total 
RNA from IP input worked well (Section 4.3.2). Also the RNA yields were 
proportional to the number of RiboTag expressing cells and were like expected from 
previous RiboTag experiments for the different Rtag/Cre mouse lines  
(Section 4.3.2). 
With an average of around 31,000,000 reads for each sample a good  
RNA-sequencing run was performed with enough reads to study gene expression 
changes within our different conditions. Quality control of all individual reads also 
showed that the RNA-sequencing run was well performed. No read had to be 
discarded because of its length, 100% of all reads had a length of 50 bp. Only a 
small number of reads had a bad quality score or more than two ambiguous 
nucleotides within the 50 bp reads. After trimming of these reads with a bad quality 
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score or too high ambiguous base content even more than 99.5% of all reads were 
left and could be used for DEG analysis, confirming the good RNA-sequencing 
performance (Section 4.3.3). 
 
5.4 Comparison of the two RNA-sequencing data analyses  
 
RNA-sequencing is used to estimate gene and transcript expression and became 
the standard method for transcriptome analysis. It is based on the number of reads 
that can be mapped to a genome sequence. There is no optimal analysis method 
for RNA-sequencing data. Every RNA-sequencing experiment can have different 
optimal methods for expression value quantification, normalization and DEG 
analysis (Conesa et al. 2016). 
The raw read counts are not sufficient to compare expression levels between 
different samples to identify expression changes since raw read values are affected 
by many factors like transcript length, library size and sequencing biases. The 
RPKM value is a normalized expression value, in which feature-length and  
library-size effects were removed. RPKM is the most reported RNA-sequencing 
expression values (Conesa et al. 2016). The DESeq2 package has its own read 
count normalization and needs an absolute gene expression value as input. 
Therefore, RPKM value can not be used as input. The DESeq2 normalization 
corrects for library size and RNA composition bias (Love et al. 2014). Therefore, 
UER and total gene reads as absolute, not normalized expression values were 
taken in the two different RNA-sequencing analyses. 
 
We predicted that if our RNA-sequencing data analysis results were robust, the 
overall results would be similar when using different analysis methods (Section 4.5). 
The analyses mainly differ in the method expression values are counted for the 
DEG analysis, unique exon reads and total gene reads. Furthermore, the two 
analyses differ in the software and web applications used for quality control, 
trimming, mapping of the RNA-sequencing reads and the mouse reference genome 
used. 
Overall, the results of the two types of analyses are quite similar except for absolute 
statistical value differences (for example in the GABAergic neuron dataset at  
10 wpi). The different absolute statistical values were unexpected, because the 
DESeq2 package calculating the statistical values was used for both analysis 
methods. However, in the analysis based on total gene reads the padj value was 
Discussion 
 
102 
 
recalculated using the Benjamini-Hochberg procedure after filtering of the DEG 
output list. This recalculating can make a difference if the DESeq2 output results in 
a lot of genes with a significant pval but have a not available padj value. If padj 
value is taken for the DEG cutoff, these genes with the not available padj value 
would be eliminated from the pathway and gene ontology analysis. Therefore, 
recalculating the padj was also tested for the analysis based on unique exon reads. 
Nevertheless, recalculated padj values after filtering of the list and the DESeq2 
calculated padj values were identical up to the third decimal place. Thus, the 
number of DEGs in analyses with recalculated and DESeq2 calculated padj value 
with the same statistical cutoff stayed more or less the same since not many genes 
with a significant pval had a not available padj value. The differences we detect in 
the two RNA-sequencing data analyses tested in this study have to be caused by 
the different expression values used for DEG analysis and the different processing 
(trimming and mapping) of the sequencing reads. 
The lists of DEGs for each cell type sorted by pval or padj are highly overlapping in 
both analyses. Altered canonical pathways and GO terms are also similar or 
identical for the different cell types. Of course, the DEG lists of the two analyses are 
not 100% identical. Genes detected as differentially expressed in one analysis are 
often close to but not within our stringent statistical cutoff in the other analysis, again 
confirming that both types of analysis are similar with highly overlapping results. 
 
Since the two DEG analyses of the RNA-sequencing data are similar but not 
identical shows that the use of different expression values, different analyzing tools 
and different analysis parameters has a strong influence on the results. It is to be 
expected that the accordance of results obtained from different RNA-sequencing 
analysis tools is sometimes low and that the results are affected by different 
parameter settings. This is especially true for low expressed genes (Conesa et al. 
2016). Therefore, it is difficult to decide which method is the better choice. UER and 
total gene read counts differ in the case if reads can be mapped to different genes. 
There are two possibilities if reads can be mapped to different annotated genes. 
The first strategy is to discard these reads, keeping only uniquely mapping reads for 
expression estimation or doing the DEG analysis directly with the UER value. A 
second strategy is to count these reads to genes in proportion to coverage by 
uniquely mapping reads. Indeed, the second strategy was reported to show 
expression values that are more comparable with microarray results and it is better 
for genes lacking unique exons (Li et al. 2010, Kukurba and Montgomery 2015).   
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5.5 Cell-type specificity 
 
To demonstrate the cell type specificity of the RiboTag method and the resulting 
immunoprecipitated cell-type-specific mRNA, enrichment or depletion of known cell 
type marker genes compared to the total RNA input was investigated (Section 4.6.1, 
Section 4.7.1). The results based on the RNA-sequencing data show that IP 
harvested mRNA was cell-type-specific since expected enrichment or depletion of 
specific cell type markers was detected, again demonstrating that the RiboTag IP 
and mRNA isolation worked well. Noteworthy, because the comparison is against 
the total RNA input the RNA of the cell type of interest is always present in this input 
sample. Thus, the more abundant a cell type is, the less is the enrichment of known 
marker genes of this cell type, but the greater the depletion of other cell type 
markers. Conversely, the less abundant a cell type is, the higher the enrichment of 
marker genes, but the lesser the depletion of cell type specific marker genes. 
However, it has to be mentioned that most cell type markers are not completely 
unique for just one brain cell type. It is often just more abundant in a specific cell 
type compared to other cells to make it a cell type marker. With RNA-sequencing 
we also detect astrocyte marker mRNA in neurons and neuronal marker mRNA in 
astrocytes. The RNA-sequencing expression value is often not so little that it could 
be just background contamination within the RiboTag IP method; often the 
expression value is in the two-digit range and therefore not only expressed or 
detected by chance. To eliminate genes that are probably not expressed a minimum 
UER filter was used (baseMean UER ≥5). GFAP is a very good example; it is highly 
expressed in our astrocyte samples but it is also expressed to a lesser extent in our 
neuron samples (RML vs. NBH; Glut base mean UER: 65.4; Astro base mean  
UER: 668.3). This mRNA is well known as an astrocyte and ependymocyte marker 
in the central nervous system, but GFAP mRNA can also be detected in mature 
neuronal cells (Zhang et al. 2014). In our study we detected a significant up 
regulation caused by RML induced neurodegeneration at 18 wpi for all cell types. At 
10 wpi glutamatergic neurons, PV neurons and astrocytes show an up regulation of 
GFAP with a statistical cutoff of pval<0.05 (not with padj<0.1) caused by RML. 
Nonetheless, this was surprising since GFAP was not increased in IHC experiment 
at the 10 wpi time point. This up regulation of GFAP in neurons was also reported 
for other NDs (Hol et al. 2003). In another transcriptome study using a system 
similar to RiboTag, GFAP was also found to be expressed in motor neurons and it 
was up regulated upon induction by mutant superoxide dismutase 1 in a mouse 
model of amyotrophic lateral sclerosis (Sun et al. 2015).  
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5.6 Gene expression regulation 
 
With both RNA-sequencing analyses we found thousands of genes expressed in the 
brain (even with a minimum expression value filter). We found that although the  
18 wpi time point represented the beginning of clinical disease, the gene expression 
changes in the mouse brain were really drastic. Differential gene expression 
analysis at 18 wpi resulted in too many changes for an in-depth gene expression 
analysis of which cells were most affected and what were the most changed 
molecular pathways and gene ontology terms (Section 4.6.2, Section 4.7.2). That 
the gene expression changes were so drastic at the 18 wpi disease time point was 
unexpected, since the freely moving mice appeared normal by passive observation 
at this time point, showing that the RiboTag method and RNA-sequencing is really 
sensitive to detect early gene expression changes in disease process. However, 
using the statistical cutoff of padj<0.1 the 10 wpi disease time point was quite 
interesting for in-depth gene expression analysis.  
First, with the analysis based on unique exon reads we found glutamatergic neurons 
were changing. However, GABA neurons, and the GABAergic subtypes (PV 
neurons and SST neurons) were unaltered. Moreover, we found that astrocytes are 
highly altered (Section 4.6.2, Section 4.7.2). Finding three cell types were not 
altered with these standard cutoff of padj<0.1 shows that this cutoff is very stringent, 
enabling detection of very early changes in gene expression and confirming that the 
10 wpi time point is well before clinical disease. 
With the analysis based on total gene reads the GABAergic neurons were also 
found to be altered (Section 4.7.2). In both analyses the top changed genes sorted 
by pval and padj were mainly the same in GABAergic neurons. However, the 
absolute calculated statistical values of both analyses were different. With a less 
stringent cutoff the same canonical pathways and GO terms can be found in the 
DEG analysis based on unique exon reads, showing that both kinds of  
RNA-sequencing data analysis are providing similar results. 
 
Glutamatergic neurons have more up regulation within differentially expressed 
genes, whereas GABAergic neurons (in the total gene read analysis) and astrocytes 
show more down regulation within the differentially expressed genes (Section 4.6.2, 
Section 4.7.2). A higher proportion of up regulation is more likely to be an active 
response to the emerging disease or a maintenance of cellular function operations, 
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whereas a down regulation is more likely to be a shutdown of cellular functions and 
a changeover into a passive, energy and cell resources saving resting state. This 
different direction of gene expression regulation in our cell types already shows that 
different cell types react differently to the same ND. 
Comparison of the differentially expressed genes of the specific cell types with little 
overlap also demonstrates that individual cell types respond to the same ND 
differently (Section 4.6.2, Section 4.7.2). Canonical pathway analyses also support 
our conclusion of cell-type specific responses caused by the same RML induced 
neurodegeneration. In summary, these results support our hypothesis that the 
phenomenon of selective vulnerability is caused by specific brain cells having 
unique strategies and capacities to cope with an emerging neurological disorder, 
RML prion disease in our study. 
 
Interestingly, we found astrocytes to be highly altered and the most affected cell 
type in our study at the early 10 wpi disease time point. Therefore, astrocytes are 
probably the earliest affected cell type in RML prion disease. Studies of NDs are 
normally confined to neurons and neuronal death, showing the most targeted 
neuron type. In Alzheimer’s disease cortical cholinergic neurons and hippocampal 
neurons are targeted, in Parkinson’s disease dopaminergic neurons in the 
substantia nigra are targeted and in Huntington’s disease neostriatal spiny neurons 
are affected (Graveland et al. 1985, Francis et al. 1999, Saxena and Caroni 2011, 
Sulzer and Surmeier 2013). In several studies GABA neurons were reported to be 
most vulnerable in different genetic NDs (Ferrer et al. 1993, Guentchev et al. 1997, 
Guentchev et al. 1998, Guentchev et al. 1999). In addition to neurons, other cells, 
namely neuroglia or vascular cells, are involved in the disease process influencing 
the selective vulnerability in neurodegeneration (Jackson 2014). If astrocytes are 
the first cell type to be affected and considering the various tasks in the brain to 
support neurons and neuronal network functioning (Araque and Navarrete 2010, 
Kimelberg and Nedergaard 2010), it is not surprising that later also neurons would 
be affected. 
 
Surprisingly, investigating TSE as a model of a protein misfolding disease, we 
detect only little or no unfolded protein response (UPR) at our 10 wpi disease time 
point. A lot of members of the UPR pathways need to be phosphorylated for their 
activation, IRE1α, PERK or eIF2α for example (Ron and Walter 2007, Oslowski and 
Urano 2011). However, we are not able to detect this kind of activation with our 
analysis method. The RiboTag method combined with RNA-sequencing is in this 
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case limited to detect only pathways in which members are up or down regulated on 
their actively translated mRNA level. However, heat shock proteins and chaperones 
are part of the unfolded protein response and are known to be differently regulated 
(typically increased expression) in neurodegeneration caused by misfolded proteins 
(van Noort et al. 2016, Sweeney et al. 2017). At the 10 wpi time point there were 
few gene expression changes for heat shock proteins and chaperones. However, 
we know from other projects that gene expression changes within heat shock 
proteins and chaperones are detectable with the RiboTag method. Using 6h of 
sleep deprivation as a stress condition in different Rtag/Cre mice showed that a 
strong up regulation of heat shock proteins and chaperones in the sleep deprived 
group compared to an undisturbed control group is detectable in different mouse 
brain cell types (data not shown). Apparently, the UPR is not one of the earliest 
changes in our RML induced neurodegeneration in the analyzed cell types. 
 
Up regulation of immediate early genes (IEGs) can be used to detect a cellular 
stress response (Gallitano-Mendel et al. 2007, Ronkina et al. 2011). A significant up 
regulation of known IEGs is only detectable in glutamatergic neurons and astrocytes 
at 10 wpi. For example Arc, Dusp1 and Nr4a1 in glutamatergic neurons or Arc, Jund 
and Nr4a1 in astrocytes are up regulated IEGs in these cell types. With a cutoff of 
pval<0.05 also Egr1, Egr2, Fos, Homer1 and Junb in glutamatergic neurons or Fos, 
Jun, and Junb in astrocytes are also up regulated. These results reflect a high 
number of significant up regulated IEGs in glutamatergic neurons and astrocytes, 
but not in GABAergic neurons or GABAergic subtypes. However, IEGs are up 
regulated in GABAergic cell types by another stress condition, namely the above 
mentioned RiboTag sleep deprivation experiment (data not shown). When cell types 
show no gene expression regulation due to the emerging prion disease like an up 
regulation of stress response pathways, the question arises whether they cannot 
detect the ongoing disease or are just not affected. Though, these data show that 
specific cell types not only respond to the same ND differently, but also the same 
cell type reacts to different stressors (RML infection or sleep deprivation) differently. 
 
5.6.1 Gene expression regulation in glutamatergic neurons 
 
Both next generation sequencing analyses show that glutamatergic neurons are 
altered at the preclinical disease time point (Section 4.6.3, Section 4.7.3). Most 
prominent pathways and gene ontology terms altered in glutamatergic neurons are 
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associated with actin, actin binding and cytoskeleton components including 
spectrins. Furthermore, molecular transport, cellular assembly and organization, cell 
morphology, signaling and cell death and survival are changed. Cellular 
compartment analysis detects genes in organelles and synapses to be enriched 
within the DEGs. 
These results suggest, along with the up regulation of most mRNAs, that 
glutamatergic neurons try to maintain the signal transduction. Furthermore, 
necessary functions for signal transduction are also maintained including functional 
actin and cytoskeleton for cellular transport to the synapse. Signal transduction and 
the cytoskeleton are closely linked (Forgacs et al. 2004). The enriched organelle 
cellular compartment also includes vesicles, necessary for cellular transport and 
signal transduction at the synapses. 
Enrichment of actin and cytoskeleton gene ontology terms also indicates an active 
stabilization of the glutamatergic cells. Stabilization of cells is an important function 
of the cytoskeleton (Huber et al. 2013). All these results indicate that the 
glutamatergic neurons recognize the emerging disease and react with maintenance 
of their most important cell functions. Because glutamate is the most abundant 
excitatory neurotransmitter in the brain (Meldrum 2000), functional glutamatergic 
neurons and glutamatergic signaling is essential in the central nervous system. 
The detected effects on glutamatergic neurons could also be indirectly caused by 
the highly altered astrocytes, normally having functions to support neurons (Araque 
and Navarrete 2010, Kimelberg and Nedergaard 2010). Neuroglia, especially 
astrocytes, control and modulate extracellular glutamate levels. Under healthy 
conditions an adequate level of glutamate is provided by the glutamate-glutamine 
cycle. Extracellular glutamate near synapses is taken up by astrocytes and 
metabolized to glutamine. Glutamine is internalized by neurons and then converted 
back to glutamate (Rothman et al. 2003). Non healthy astrocytes could have 
problems performing this function. This would lead to an accumulation of glutamate 
outside cells near synapses, eventually causing excitotoxicity which is known to 
occur in several NDs (Hynd et al. 2004, Salinska et al. 2005). Another possibility is 
that the astrocytes still take up the glutamate but no glutamine is sent back to the 
neurons.  
However, with analysis based on total gene reads no transport gene ontology terms 
are detectable. Instead, gene ontology terms associated with transcription, 
transcription factors and nervous system development were revealed, showing that 
glutamatergic neurons might also try to react on the transcriptional level to the 
emerging disease. 
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5.6.2 Gene expression regulation in GABAergic neurons and subtypes 
 
With both gene expression analyses SST and PV neurons are unaltered at the  
10 wpi disease time point. The analysis based on total gene reads shows changes 
in genes involved in the IPA canonical pathway “Circadian Rhythm Signaling” in 
overall GABAergic neurons at 10 wpi. With a less stringent cutoff the canonical 
pathway can also be found in the DEG analysis based on unique exon reads 
(Section 4.6.4, Section 4.7.4). Furthermore, if neither SST neurons nor PV neurons 
are altered, the question is which GABAergic neuron subtype is responsible for the 
gene expression change. GABAergic neurons have a high diversity and every 
subtype has its own unique features (Taniguchi 2014). 
However, all these circadian rhythm genes are also known to be involved in 
oxidative stress response (Musiek et al. 2013, Mendez et al. 2016, Musiek and 
Holtzman 2016). Therefore, there are two possibilities: the gene regulation is 
changed either due to the circadian rhythm signaling itself or as an oxidative stress 
response. If the emerging disease affects the circadian clock signaling the 
responsible neuron subtype could be GABAergic neurons within the 
suprachiasmatic nucleus (SCN) not expressing Pvalb or SST. The SCN is a small 
brain region within the hypothalamus working as the master circadian clock 
pacemaker and therefore controlling the circadian rhythm (Welsh et al. 2010). The 
SCN consists of many different cell types, however, GABAergic neurons and 
GABAergic signaling play an especially important role within the SCN (Liu and 
Reppert 2000, DeWoskin et al. 2015, Myung et al. 2015). The GABAergic subtype is 
probably VIP expressing neurons because it was reported that the GABAergic 
neurotransmitter gamma-aminobutyric acid colocalizes with VIP within the SCN 
(Moore and Speh 1993). It is also reported that there is a connection between NDs, 
circadian rhythm and sleep (Hood and Amir 2017). 
If the detected gene expression change is due to oxidative stress response, another 
yet unknown GABAergic neuron subtype has to be responsible for the detected 
DEGs. Finding SST neurons and PV neurons to be unaltered already narrows down 
the potential candidate subtypes. Surprisingly, with activation of the detected 
BMAL1 associated transcription factor complexes, the target genes responsible for 
oxidative stress response are not up regulated. Known analyzed redox genes are 
unchanged or, like DBP, significantly down regulated. However, DBP is also in the 
RiboTag sleep deprivation experiment significantly down regulated (data not 
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shown), but also known as one of the down regulated sleep deprivation marker 
genes (Wisor et al. 2008, Thompson et al. 2010). If an oxidative stress response is 
being attempted by GABAergic neurons, the question is whether this is not 
successful with a significant change of redox genes or is hindered by further gene 
expression regulation on a different level than mRNA. 
The fact that GABAergic neurons show no or little reaction at the early disease time 
point could also be responsible for the fact that they are reported to be most 
vulnerable in several NDs (Ferrer et al. 1993, Guentchev et al. 1997, Guentchev et 
al. 1998, Guentchev et al. 1999). This strong vulnerability could be caused by the 
fact that these cell types fail to induce a strong enough protective reaction to the 
emerging disease to stay healthy and survive. 
 
5.6.3 Gene expression regulation in astrocytes 
 
Astrocytes show a highly altered, cell-type-specific disease response with both next 
generation sequencing analyses at the 10 wpi time point (Section 4.6.5, Section 
4.7.5). Therefore, astrocytes are probably the most and earliest affected cell type in 
our study. DEGs changed are mainly down regulated ribosomal proteins (21 of 145 
genes associated with KEGG pathway “Ribosome”) and down regulated members 
of the electron transport chain (cytochrome c and four of five complexes are 
affected). The upstream regulators responsible for this massive down regulation in 
astrocytes were also detected. The top regulator is RICTOR, it is associated with 
most of the down regulated ribosomal proteins and most of the proteins altered in 
the electron transport chain. Therefore, an activation of RICTOR is predicted. 
Altered molecular and cellular functions are cell death and survival, lipid 
metabolism, small molecule biochemistry, gene expression and protein synthesis. 
Nearly all DEGs in astrocytes are down regulated, indicating that astrocytes going 
into a resting state stopping to maintain their normal function. 
Down regulated members of the electron transport chain in mitochondria lead to a 
mitochondrial dysfunction in astrocytes. Several TSEs and other NDs are known to 
show altered mitochondria function and mitochondrial dysfunction in different brain 
regions caused by the disease (Ferrer 2009, Ansoleaga et al. 2016, Frau-Mendez et 
al. 2017). In addition, some of these studies show altered protein synthesis during 
TSEs (Ansoleaga et al. 2016, Frau-Mendez et al. 2017). In our cell-type specific 
study we can detect that these changes of protein synthesis and energy metabolism 
are caused by astrocytes at an early time point, even before clinical disease. 
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Expression changes, namely a down regulation, of ribosomal proteins do not 
necessarily lead to a shutdown or decrease of protein synthesis. With expression 
changes of ribosomal proteins also the assembly of the ribosome can be altered to 
react to specific conditions to control protein synthesis of specific mRNAs (Xue and 
Barna 2012, Preiss 2016, Shi et al. 2017). Either the astrocytes reduce protein 
synthesis for energy saving reasons or actively react with a change in the 
availability of certain ribosomal proteins to the RML induced stress situation. For 
energy saving reasons it would make sense to reduce production of ribosomes. 
Biogenesis of ribosomes is the most energy consuming process in a cell (MacInnes 
2016). 
Using the RiboTag method for isolation of ribosome associated mRNA, the 
regulation of ribosomal proteins does not affect our results. Initially, the HA bearing 
ribosomal protein (Rpl22) is not regulated by RML prion infection. This is true for all 
cell types. Therefore, in all cell types the level of Rpl22 is the same in control and 
RML groups, suggesting that the different groups also have the same amount of HA 
bearing ribosomes. Furthermore, RiboTag is a sampling technique and often not all 
captured mRNA is analyzed. The amount of captured mRNA or differences of 
mRNA amounts between groups do not affect the DEG analysis. There are several 
normalization steps within the analysis of gene expression changes; for example, 
the DEG analysis included a sample normalization step (correction for library size 
and RNA composition bias) and the same absolute amounts of mRNA were used 
for RNA-sequencing. 
Astrocytes perceive the ongoing disease at this preclinical time point and respond to 
the emerging disease with a massive down regulation of genes required for protein 
synthesis and respiration. Detected effects on other cell types could be indirectly 
caused by the highly altered astrocytes. Astrocytes have lots of functions supporting 
neurons (Araque and Navarrete 2010, Kimelberg and Nedergaard 2010). Non 
healthy astrocytes could have problems performing these functions, leading to 
adverse effects on neurons and other brain cell types. 
 
5.7 Summary findings of RML infection 
 
The summary findings of gene expression changes in specific mouse brain cells at 
10 wpi and neuropathological changes at 18 wpi caused by RML prion infection are 
shown in figure 5.7. 
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Figure 5.7: 10 wpi: Gene expression analyses demonstrate that glutamatergic neurons 
(green) react to RML prion infection with a maintenance of signal transduction and 
stabilization of the cell / cytoskeleton. GABAergic neurons (orange) show changes in 
circadian rhythm or oxidative stress response. GABAergic neuron subtypes (orange), 
namely SST neurons and PV neurons are unaltered. In astrocytes (blue) a reduction / 
change of protein synthesis and a mitochondrial dysfunction is detectable. 18 wpi: 
Neurophalological analyses demonstrate astrogliosis (dark blue, large astrocytes), reactive 
microglia (yellow), prion aggregation (black grids) and neurodegeneration (dashed lines).  
 
5.8 Outlook 
 
This work gives clues into which brain cells are affected earliest and most severely 
and how they respond to the emerging disease. Of course, we were limited in our 
study to a certain number of cell types to investigate. In our study astrocytes are the 
most and probably earliest affected cell type by RML induced neurodegeneration. In 
retrospect, it would be interesting to study if other subtypes of neuroglia are also 
highly affected by RML and how they respond to the emerging disease. If other 
neuroglia subtypes are affected earlier than neurons it would also be worth 
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investigating if their impairment has adverse effects on neurons or other neuroglia 
cell types. It is not surprising that when astrocytes, with their diverse supporting 
functions for neurons, are affected, neurons quickly show changes caused by this 
astrocyte functional impairment. This study provides evidence that for therapeutic 
approaches and a better understanding of mechanism in NDs a further investigation 
of the role of neuroglia, especially astrocytes, is essential. Other studies also show 
the important role of neuroglia for a functional central nervous system (Kimelberg 
and Nedergaard 2010) or a neuroprotective role during prion disease (Zhu et al. 
2016). 
We were also limited in the number of disease time points in our study. With 
hindsight, it would have been interesting to have more disease time points in 
addition to the chosen ones, especially with regard to the drastic gene expression 
regulation at the 18 wpi time point. This would lead to a better understanding of the 
course of the RML induced neurodegeneration at the level of gene expression 
regulation. 
Furthermore, in addition to the RML induced neurodegeneration other scrapie 
strains, prion diseases or models of NDs could be used to investigate if the results 
are robust for different TSEs or even other NDs. In addition to actively translated 
mRNAs, other levels of gene expression including protein levels, protein activation, 
micro RNAs or even epigenetic changes and features could be analyzed. Using 
different disease models and different levels of gene expression in a  
cell-type-specific manner is needed for a better understanding of disease 
mechanisms, a better understanding of the selective vulnerability in NDs and for 
developing therapies. 
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6. Summary 
 
Why neurodegenerative diseases target specific brain regions is poorly understood. 
We hypothesize that this selective vulnerability is caused by specific brain cells in 
these regions having unique strategies and capacities to cope with various disease 
related protein conformers that ultimately fail. 
To study how specific cell types in the mouse brain respond to a neurodegenerative 
disease we used prion infection (RML scrapie strain) as a model of 
neurodegenerative disease. RML infection was combined with the RiboTag method 
to isolate ribosome associated mRNA from specific brain cell types. Mice 
expressing the epitope-tagged ribosomes specifically in astrocytes or subsets of 
neurons, including glutamatergic, GABAergic, parvalbumin or somatostatin neurons, 
were injected with brain homogenate from either normal or prion infected mice. 
Changes to gene expression were analyzed by next generation sequencing at a 
stage when clinical signs first become apparent (18 wpi) and at a much earlier stage 
(10 wpi) in the disease process. Neuropathological changes like microglia 
activation, astrogliosis, aggregated prions and spongiosis were analyzed by 
different IHC stainings. This work gives clues into which cells are affected earliest 
and how they respond to the emerging disease. Investigating cell-type-specific 
mechanisms of selective vulnerability are needed for a better understanding of 
mechanism in NDs and developing therapies. 
 
At disease onset (18 wpi) an extensive regulation of gene expression is detectable, 
although mice show obviously no changes in their phenotype. Gene expression 
changes at 18 wpi were drastic with too many changes for an in-depth gene 
expression analysis of which cells were most affected and what were the most 
changed molecular pathways. To detect which cells are affected earliest and how 
they respond to the emerging disease the early disease time point (10 wpi) was 
chosen for analysis. First, we found glutamatergic neurons were changing. 
However, PV neurons and SST neurons were unaltered. Moreover, we found that 
astrocytes are highly altered and probably the most and earliest affected cell type. 
GABAergic neurons were found to be changed depending on the statistical output of 
two different next generation sequencing data analyses. 
Glutamatergic neurons have more up regulation within differentially expressed 
genes, whereas GABAergic neurons and astrocytes show more down regulation 
within the differentially expressed genes. Comparison of the differentially expressed 
Abstract 
 
114 
 
genes of the different cell types with little overlap demonstrates that individual cell 
types respond to the same RML induced neurodegeneration differently. 
Canonical pathway analysis show actively translated mRNAs changed in the 
astrocytes are mainly ribosomal proteins and members of the electron transport 
chain leading to an impairment or change of gene expression and a mitochondrial 
dysfunction. Glutametergic gene ontology analysis possess genes associated to 
actin, actin binding, cytoskeleton, cellular transport and signaling, probably leading 
to a stabilization of the cell and maintenance of essential glutamatergic neuron 
functions like signal transduction. GABAergic neurons show changes based on 
gene read analysis in genes involved in circadian rhythm signaling. All these 
circadian rhythm genes are also known to be involved in oxidative stress response. 
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